CUMULATIVE SUPPLEMENT 8
JAN'98-AUG'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 8

AUGUST 1998

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

IV

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

V

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)
JONES MEDICAL INDUSTRIES INC (JONES MEDCL INDS)	JONES PHARMA INC (JONES PHARMA)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

VI

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet. There is more than one media users may select to access these files.

Preface and ASCII Text Files:
The Preface may be accessed using this URL: http://www.fda.gov/cder/orange/adp.htm. Users who wish to download the Prescription Drug Product List; OTC Drug Products and Discontinued Drug Products lists may access the ASCII text files using this URL: htttp://www.fda.gov/cder/orange/obreadme.htm. The drug product lists and the zipobtxt.exe files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and B are updated twice a year.

Preface and Searchable Query Database:
The Preface may be accessed using this URL: http://www.fda.gov/cder/ob/docs/preface/ectablec18.htm. Users who wish to query on a specific drug product may access the database using this URL: http://www.fda.gov/cder/ob. The Query enables searching of the database by active ingredient, proprietary name, applicant holder or applicant number. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

V 11

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711	9768	
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)	2494 (25.6%)	
MULTISOURCE	7052 (73.3%)	7117 (73.3%)	7164 (73.3%)	
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)	6790 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)	374 (3.8%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	--	8	9	
NUMBER OF APPLICANTS	551	529	538	

[1]Amino acid-containing products of varying composition (see Introduction. page xx of the List).

IX

ACARBOSE

TABLET; ORAL

PRECOSE

		● BAYER	25MG	N20482 004 MAY 29, 1997
			25MG	N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

> ADD >	AB	MALLINCKRODT	325MG;50MG;40MG	N87804 001 JAN 24, 1985
> ADD >	AB	+ MIKART	500MG;50MG;40MG	N89451 001 MAY 23, 1988
> ADD >	AB	WATSON LABS	500MG;50MG;40MG	N40267 001 JUL 30, 1998
> DLT >		REPAN		
> DLT >	AB	MALLINCKRODT	325MG;50MG;40MG	N87804 001 JAN 24, 1985
> DLT >				

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	ROYCE LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA		300MG;30MG	N89998 001 DEC 28, 1994
AA		300MG;60MG	N89999 001 DEC 28, 1994
AA	WATSON LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA		300MG;30MG	N89998 001 DEC 28, 1994
AA		300MG;60MG	N89999 001 DEC 28, 1994

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051 001 AUG 28, 1992

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001 MAR 13, 1998

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998
AA		500MG;10MG	N40201 002 FEB 27, 1998
AA	ROYCE LABS	500MG;7.5MG	N40123 003 MAR 04, 1996
AA		500MG;5MG	N40122 001 MAR 04, 1996
AA		500MG;7.5MG	N40123 004 MAR 04, 1996
AA		650MG;7.5MG	N40123 001 MAR 04, 1996
AA		650MG;10MG	N40123 002 MAR 04, 1996
AA		750MG;7.5MG	N40122 002 MAR 04, 1996
AA	WATSON LABS	500MG;2.5MG	N40123 003 MAR 04, 1996
AA		500MG;5MG	N40122 001 MAR 04, 1996
AA		500MG;7.5MG	N40123 004 MAR 04, 1996
AA		650MG;7.5MG	N40123 001 MAR 04, 1996
AA		650MG;10MG	N40123 002 MAR 04, 1996
AA		750MG;7.5MG	N40122 002 MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

>ADD<	AA	MALLINCKRODT	500MG;5MG	N40257 001 AUG 04, 1998
>ADD<	AA	ROYCE LABS	500MG;5MG	N40234 001 OCT 30, 1997
	AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

	AA	DURAMED	325MG;5MG	N40272 001 JUN 30, 1998
	AA	ROYCE LABS	325MG;5MG	N40171 001 OCT 30, 1997
	AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

	AA	ROYCE LABS	650MG;65MG	N40139 001 DEC 16, 1996
	AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

	AT	B BRAUN	250MG/100ML	N18161 001
	AT	MCGAW	250MG/100ML	N18161 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

	AB	CHELSEA LABS	200MG	N75101 001 APR 15, 1998
	AB	GENPHARM	200MG	N74977 001 APR 13, 1998

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR

	AB	COPLEY PHARM	400MG	N75021 001 MAR 18, 1998
	AB		800MG	N75021 002 MAR 18, 1998
	AB	GENPHARM	400MG	N74976 001 APR 13, 1998
	AB		800MG	N74976 002 APR 13, 1998
	*	NOVOPHARM	200MG	N74556 001 APR 22, 1997
	@		200MG	N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

	AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998
	+	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998
	AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
	AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
	AP	FUJISAWA	EQ 500MG BASE/VIAL	N74930 001 MAY 13, 1998

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

	+	FUJISAWA HLTHCARE	3MG/ML	N19937 002 OCT 30, 1989
	*	MEDCO RES	3MG/ML	N19937 002 OCT 30, 1989

ADENOSCAN

	+	FUJISAWA HLTHCARE	3MG/ML	N20059 001 MAY 18, 1995
	*	MEDCO RES	3MG/ML	N20059 001 MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE	N75050 001	JUN 18, 1998
AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001	JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001	JAN 30, 1998
AA	NOVA	EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994
@		EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM

>ADD>	+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996
>ADD>					
>DLT>	+	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996
>DLT>					

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	GENEVA PHARMS	2MG	N74909 001	MAR 25, 1998
AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997
AB	WATSON LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	BEDFORD	0.5MG/ML	N74815 001	JAN 20, 1998

PROSTIN VR PEDIATRIC

AP	+ PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001	
	+	0.5MG/ML	N18484 001	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL

>DLT> AB	ROSEMONT	100MG	N70589 001	AUG 05, 1986
>DLT>				
>ADD> AB	+	100MG	N70589 001	AUG 05, 1986
>ADD>				
>DLT>	SYMMETREL			
>DLT>	+ ENDO PHARMS	100MG	N16020 001	
>ADD>	@	100MG	N16020 001	

SYRUP; ORAL
SYMMETREL

AA	+ DUPONT MERCK	50MG/5ML	N16023 002
AA	+ ENDO PHARMS	50MG/5ML	N16023 002

TABLET; ORAL
SYMMETREL

	@ ENDO PHARMS	100MG	N18101 001
	+	100MG	N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT

	+ LEDERLE	0.1%	N18498 001
	+ WYETH AYERST	0.1%	N18498 001

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
MIDAMOR

>ADD> AB	+ MERCK	5MG	N18200 001	
>DLT> AB	+ MERCK SHARP DOHME	5MG	N18200 001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB		ROYCE LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991
AB		WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991

MODURETIC 5-50

> ADD >	AB	+	MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001
> DLT >	AB	+	MERCK SHARP DOHME	EQ 5MG ANHYDROUS;50MG	N18201 001

AMINO ACIDS

INJECTABLE; INJECTION
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

> ADD >		+	BAXTER HLTHCARE	20%	N20849 001 AUG 26, 1998

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE

AB	+	WYETH AYERST	200MG	N18972 001 DEC 24, 1985

PACERONE

AB		UPSHER SMITH	200MG	N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB		ROYCE LABS	10MG;2MG	N73007 001 OCT 17, 1991
AB			10MG;4MG	N73009 001 OCT 17, 1991
AB			25MG;2MG	N73008 001 OCT 17, 1991
AB			25MG;4MG	N73010 001 OCT 17, 1991
AB		WATSON LABS	10MG;2MG	N73007 001 OCT 17, 1991
AB			10MG;4MG	N73009 001 OCT 17, 1991

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB		WATSON LABS	25MG;2MG	N73008 001 OCT 17, 1991
AB			25MG;4MG	N73010 001 OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

@	B BRAUN	40MEQ/100ML	N85734 001
@	MCGAW	40MEQ/100ML	N85734 001

AMOXICILLIN

TABLET; ORAL
AMOXIL

	+	SMITHKLINE BEECHAM	500MG	N50754 002 JUL 10, 1998
	+		875MG	N50754 001 JUL 10, 1998

AMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

> ADD >	AP		ABBOTT	EQ 5MG BASE/ML	N74616 001 AUG 03, 1998

INOCOR

> ADD >	AP	+	SANOFI	EQ 5MG BASE/ML	N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	+	GENSIA	0.05MG/ML	N20420 001 SEP 12, 1997
	+	GENSIA AUTOMEDICS	0.05MG/ML	N20420 001 SEP 12, 1997

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL,ASPIRIN,CAFFEINE AND CODEINE PHOSPHATE

> ADD >	AB	STEVENS J	325MG;50MG;40MG;30MG	N74951 001	
> ADD >				AUG 31, 1998	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB	PAR PHARM	385MG;30MG;25MG	N75141 001	
			MAY 29, 1998	

ORPHENGESIC FORTE

AB	PAR PHARM	770MG;60MG;50MG	N75141 002	
			MAY 29, 1998	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA	HALSEY	325MG;4.5MG;0.38MG	N40260 001	
			JUL 17, 1998	
AA	WATSON LABS	325MG;4.5MG;0.38MG	N40255 001	
			FEB 27, 1998	

ATENOLOL

TABLET; ORAL
ATENOLOL

> ADD >	AB	GENPHARM	25MG	N74126 003	
> ADD >				AUG 26, 1998	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	MARTEC	50MG;25MG	N74404 001	
			MAY 14, 1998	
AB		100MG;25MG	N74404 002	
			MAY 14, 1998	

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PARKE DAVIS	EQ 10MG BASE	N20702 001		
			DEC 17, 1996		
		EQ 20MG BASE	N20702 002		
			DEC 17, 1996		
*		EQ 40MG BASE	N20702 003		
			DEC 17, 1996		
	WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001		
			DEC 17, 1996		
		EQ 20MG BASE	N20702 002		
			DEC 17, 1996		
+		EQ 40MG BASE	N20702 003		
			DEC 17, 1996		

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	MARSAM	10MG/ML	N74945 001	
			JUL 28, 1998	

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	MARSAM	10MG/ML	N74944 001	
			JUL 28, 1998	

BACITRACIN

POWDER, FOR RX COMPOUNDING
BACITRACIN

	PADDOCK	5,000,000 UNITS/BOT	N62456 001	
			JUL 27, 1983	
@		5,000,000 UNITS/BOT	N62456 001	
			JUL 27, 1983	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

> DLT >	AP	* GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
> DLT >			10,000 UNITS/GM	N50414 002	
> ADD >	AT	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
> ADD >			10,000 UNITS/GM	N50416 002	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		NEOSPORIN			
AT	*	GLAXO WELLCOME	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50417 001
AT	+	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50417 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		BACITRACIN ZINC AND POLYMYXIN B SULFATE			
AT		ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM		N64028 001 JAN 30, 1995
AT		AKORN	500 UNITS/GM; 10,000 UNITS/GM		N64028 001 JAN 30, 1995
		POLYSPORIN			
AT	*	GLAXO WELLCOME	500 UNITS/GM; 10,000 UNITS/GM		N61229 001
AT	+	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM		N61229 001

BACLOFEN

TABLET; ORAL

		BACLOFEN			
AB		RX CR LABS	10MG		A73092 001 JAN 28, 1994
AB			20MG		A73093 001 JAN 28, 1994
AB		WATSON LABS	10MG		A73092 001 JAN 28, 1994
AB			20MG		A73093 001 JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

		VASCOR			
		JOHNSON RW	300MG		N19002 002 DEC 28, 1990
	*		400MG		N19002 003 DEC 28, 1990

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

		VASCOR			
	+	JOHNSON RW	300MG		N19002 002 DEC 28, 1990
	@		400MG		N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL

		BETAMETHASONE VALERATE			
AB		CLAY PARK	EQ 0.1% BASE		A70053 001 JUN 10, 1986
	@		EQ 0.1% BASE		N70053 001 JUN 10, 1986

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

		AZOPT			
	+	ALCON	1%		N20816 001 APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL

		BROMOCRIPTINE MESYLATE			
AB		LEK PHARM	EQ 2.5MG BASE		A74631 001 JAN 13, 1998
		PARLODEL			
AB	+	NOVARTIS	EQ 2.5MG BASE		N17962 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		ZYBAN			
	*	GLAXO WELLCOME	100MG	> DLT >	N20711 001 MAY 14, 1997
	@		100MG	> ADD >	N20711 002 MAY 14, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

> ADD > BUTORPHANOL TARTRATE

> ADD > AP BEDFORD 2MG/ML N75046 001
AUG 12, 1998

> ADD > BUTORPHANOL TARTRATE PRESERVATIVE FREE

> ADD > AP BEDFORD 1MG/ML N75045 001
AUG 12, 1998

> ADD > AP 2MG/ML N75045 002
AUG 12, 1998

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001
JUN 10, 1993

MCGAW 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001
DEC 20, 1993

MCGAW 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001
DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N18256 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N20000 001
APR 17, 1992

AP MCGAW 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N18256 001

AP 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML N20000 001
APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

● B BRAUN 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001

● MCGAW 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N19718 001
SEP 29, 1989

MCGAW 35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML N19718 001
SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

ABBOTT [illegible] N18808 001
FEB 26, 1982

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML;
119.3MG/100ML;643MG/100ML N18608 001
FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 33MG/100ML;30MG/100ML;
860MG/100ML N18721 001
NOV 09, 1982
AP 33MG/100ML;30MG/100ML;
860MG/100ML N20002 001
APR 17, 1992
[redacted]

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 33MG/100ML;30MG/100ML;
860MG/100ML N18156 001
[redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N19632 001
FEB 29, 1988
@ 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N18023 001
[redacted]

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
[redacted]

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML;
310MG/100ML N18681 001
DEC 27, 1982
[redacted]

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001
JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
[redacted]
ASTRA PHARMS 4MG [redacted]
JUN 04, 1998
8MG N20838 002
JUN 04, 1998
16MG N20838 003
JUN 04, 1998
+ 32MG N20838 004
JUN 04, 1998

CAPECITABINE

TABLET; ORAL
XELODA

		ROCHE	150MG	N20896 001 APR 30, 1998
	+		500MG	N20896 002 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB		[redacted]	[redacted]	[redacted]
AB			[redacted]	[redacted]
AB			[redacted]	[redacted]
AB			[redacted]	[redacted]
AB		WATSON LABS	12.5MG	N74451 001 FEB 13, 1996
AB			25MG	N74451 002 FEB 13, 1996
AB			50MG	N74451 003 FEB 13, 1996
AB			100MG	N74451 004 FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/15

AB		BRISTOL MYERS SQUIBB	25MG;15MG	N18709 001 OCT 12, 1984
AB		[redacted]	[redacted]	[redacted]

CAPOZIDE 25/25

AB	+	BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
AB	§	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/15

AB	+	BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 50/15

AB	§	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/25

AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
AB		[redacted]	[redacted]	[redacted]

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		ZENITH GOLDLINE	25MG;15MG	N75055 001 JUN 18, 1998
AB			25MG;25MG	N75055 002 JUN 18, 1998
AB			50MG;15MG	N75055 004 JUN 18, 1998
AB			50MG;25MG	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

	§	[redacted]	[redacted]	[redacted]
	§		[redacted]	[redacted]
	+	SHIRE	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL
LODOSYN

	§	[redacted]	[redacted]	[redacted]
	+	DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL
SINEMET

AB		[redacted]	[redacted]	[redacted]

CARBIDOPA; LEVODOPA

TABLET; ORAL

	SINEMET				
[redacted]	[redacted]	[redacted]	[redacted]	> ADD >	
[redacted]	*	[redacted]	[redacted]	> ADD >	
AB	DUPONT PHARMS	10MG;100MG	N17555 001	> ADD >	
AB		25MG;100MG	N17555 003	> ADD >	
AB	+	25MG;250MG	N17555 002		

TABLET, EXTENDED RELEASE; ORAL

	SINEMET CR			
	[redacted]	[redacted]	[redacted]	
	*	[redacted]	[redacted]	
	DUPONT PHARMS	25MG;100MG	N19856 002 DEC 24, 1992	
	+	50MG;200MG	N19856 001 MAY 30, 1991	

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL		
AA	ROYCE LABS	350MG	N40152 001 DEC 03, 1996
AA	WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR		
AB	MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB		EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998
AB		EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM		
AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002 AUG 14, 1998
AP		EQ 500MG BASE/VIAL	N64169 001 AUG 14, 1998
AP		EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP		EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

	CEFIZOX		
*	[redacted]	[redacted]	[redacted]
*		[redacted]	[redacted]
*		[redacted]	[redacted]
		[redacted]	[redacted]
+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993
	CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER		
@	[redacted]	[redacted]	[redacted]
@	FUJISAWA HLTHCARE	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984
	CEFIZOX IN PLASTIC CONTAINER		
*	[redacted]	[redacted]	[redacted]
*		[redacted]	[redacted]
+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AP		ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP			EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP			EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB		ZENITH GOLDLINE	EQ 250MG BASE	N61969 001
AB			EQ 500MG BASE	N61969 002
AB		ZENITH LABS	[illegible]	[illegible]
AB			[illegible]	[illegible]

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

	*	LILLY	EQ 100MG BASE/ML [illegible]
	●		EQ 100MG BASE/ML N50406 003
	+		EQ 100MG BASE/ML N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN

AB	*	PARKE DAVIS	[illegible]	[illegible]
	*		[illegible]	[illegible]
	*		[illegible]	[illegible]
AB	+	PARKEDALE	250MG	N60591 002
			50MG	N60591 001
	+		100MG	N60591 003

OINTMENT; OPHTHALMIC
CHLOROMYCETIN

AB	*	PARKE DAVIS	1%	[illegible]
AT	+	PARKEDALE	1%	N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN

	*	PARKE DAVIS	[illegible]	[illegible]
	+	PARKEDALE	25MG/VIAL	N50143 001

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR

AT		PARKE DAVIS	[illegible]	[illegible]
AT		PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN

	*	PARKE DAVIS	[illegible]	[illegible]
	+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE

	*	PARKE DAVIS	[illegible]	[illegible]
	+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

	*	PARKE DAVIS	[illegible]	[illegible]
	●	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN

AB	*	PARKE DAVIS	[illegible]	[illegible]
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	+	ICN	5MG	N85482 001
	●		10MG	N85481 001
	●		25MG	N85488 001
	*	ROCHE	[illegible]	[illegible]
	●		[illegible]	[illegible]
	●		[illegible]	[illegible]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM

AB		ICN	5MG	N85461 001	> DLT
AB			10MG	N85472 001	> DLT >
AB	+		25MG	N85475 001	
AB		[illegible]	[illegible]	[illegible]	> ADD >
AB			[illegible]	[illegible]	> ADD >
AB	*		[illegible]	[illegible]	> DLT >
					> DLT >

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

AT	*	PROCTER AND GAMBLE	0.12%	[illegible]	
				AUG 13, 1986	> ADD >
AT	+	ZILA	0.12%	N19028 001	> DLT >
				AUG 13, 1986	

TABLET; DENTAL
PERIOCHIP

	+	PERIO PRODS (IS)	2.5MG	N20774 001
				MAY 15, 1998

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL

> ADD >		+ MERCK	250MG/5ML	N11870 001	
> DLT >		* [illegible]	250MG/5ML	[illegible]	

TABLET; ORAL
DIURIL

> ADD >	AB	MERCK	250MG	N11145 004	
> ADD >	AB	+	500MG	N11145 002	
> DLT >	AB	[illegible]	[illegible]	[illegible]	
> DLT >	AB	*	500MG	[illegible]	

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
DIUPRES-250

> ADD >	BP	MERCK	250MG;0.125MG	N11635 003	
> ADD >				AUG 26, 1987	

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
DIUPRES-250

	BP	[illegible]	[illegible]	[illegible]	
				[illegible]	

DIUPRES-500

> ADD >	BP	+ MERCK	500MG;0.125MG	N11635 006	
> ADD >				AUG 26, 1987	
> DLT >	BP	* [illegible]	[illegible]	[illegible]	
> DLT >				[illegible]	

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
DIURIL

> ADD >		+ MERCK	EQ 500MG BASE/VIAL	N11145 005	
> DLT >		* [illegible]	[illegible]	[illegible]	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	[illegible]	[illegible]	[illegible]	
				[illegible]
	●	25MG/ML	N89563 001	
			APR 15, 1988	

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	[illegible]	[illegible]	[illegible]	
				[illegible]
AA	WATSON LABS	500MG	N81040 001	
			AUG 22, 1989	

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001	
			MAY 28, 1998	
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002	
			MAY 28, 1998	

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE LIGHT

AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001 MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002 MAY 28, 1998

LOCHOLEST

AB	EON	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002 AUG 15, 1996
	#	EQ 4GM RESIN/PACKET	N74561 001 AUG 15, 1996
	#	EQ 4GM RESIN/SCOOPFUL	N74561 002 AUG 15, 1996

LOCHOLEST LIGHT

AB	EON	EQ 4GM RESIN/PACKET	N74562 001 AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002 AUG 15, 1996
	#	EQ 4GM RESIN/PACKET	N74562 001 AUG 15, 1996
	#	EQ 4GM RESIN/SCOOPFUL	N74562 002 AUG 15, 1996

CIMETIDINE

SOLUTION; ORAL
CIMETIDINE HCL

AA	DURAMED	300MG/5ML	N75110 001 JUN 18, 1998

TABLET; ORAL
CIMETIDINE

AB	BAKER NORTON	200MG	N74424 001 JUL 28, 1995
AB		300MG	N74424 002 JUL 28, 1995
AB		400MG	N74424 003 JUL 28, 1995
AB		800MG	N74424 004 JUL 28, 1995
AB	ZENITH LABS	200MG	N74424 001 JUL 28, 1995
AB		300MG	N74424 002 JUL 28, 1995

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	ZENITH LABS	400MG	N74424 003 JUL 28, 1995
AB		800MG	N74424 004 JUL 28, 1995

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL

AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001 JUL 09, 1998

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC
CILOXAN

+	ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC

+	BAYER	EQ 0.2% BASE;1%	N20805 001 FEB 10, 1998

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID QUICKSOLV

+	JANSSEN	EQ 20MG BASE	N20767 001 NOV 07, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
PROPULSID QUICKSOLV

+	JANSSEN	EQ 20MG BASE	N20767 001 NOV 07, 1997

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA
FOREST LABS — EQ 20MG BASE — N20822 002 JUL 17, 1998
EQ 40MG BASE — N20822 003 JUL 17, 1998
+ EQ 60MG BASE — N20822 004 JUL 17, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE
AA MORTON GROVE — EQ 0.5MG BASE/5ML — N74863 001 MAR 13, 1998

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN 3
+ PHARMACIA AND UPJOHN — EQ 2% BASE — N50680 002 MAR 02, 1998

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
AP MARSAM — EQ 150MG BASE/ML — N62913 001 OCT 20, 1988
● EQ 150MG BASE/ML — N62913 001 OCT 20, 1988

SOLUTION; TOPICAL
CLEOCIN T
AT PHARMACIA AND UPJOHN — EQ 1% BASE — N62363 001 FEB 08, 1982
● EQ 1% BASE — N62363 001 FEB 08, 1982

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE
> ADD > > ADD > AB STIEFEL — 0.05% — N75057 001 AUG 12, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL
AB MYLAN — 25MG — N74947 001 APR 30, 1998
AB 50MG — N74947 002 APR 30, 1998
AB 75MG — N74947 003 APR 30, 1998

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM
> ADD > > ADD > AB NOVOPHARM — 0.5MG — N74920 001 AUG 04, 1998
> ADD > AB 1MG — N74920 002 AUG 04, 1998
> ADD > > ADD > AB 2MG — N74920 003 AUG 04, 1998

KLONOPIN RAPIDLY DISINTEGRATING
* ROCHE — 0.125MG — [illegible]
0.25MG — [illegible]
0.5MG — [illegible]
1MG — [illegible]
* 2MG — [illegible]

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING
+ ROCHE — 0.125MG — N20813 001 DEC 23, 1997
0.25MG — N20813 002 DEC 23, 1997
0.5MG — N20813 003 DEC 23, 1997
1MG — N20813 004 DEC 23, 1997
+ 2MG — N20813 005 DEC 23, 1997

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

>_DLT_>	*	[redacted]	[redacted]	[redacted]
>_DLT_>				OCT 02, 1996
>_ADD_>	+	ROXANE	0.1MG/ML	N20615 001
>_ADD_>				OCT 02, 1996

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLY-MYCIN M

*	PARKE DAVIS	EQ 150MG BASE/VIAL	[redacted]
+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

>_DLT_>	*	PARKE DAVIS	[redacted]	[redacted]
>_DLT_>				[redacted]
>_ADD_>	+	PARKEDALE	EQ 3MG BASE/ML;10MG/ML;	
>_ADD_>			EQ 3.3MG BASE/ML;0.5MG/ML	N50356 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

@	PARKE DAVIS	[redacted]	[redacted]
@		[redacted]	[redacted]
@	PARKEDALE	25 UNITS/VIAL	N08317 002
@		40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

>_DLT_>		CAPSULE; INHALATION		
>_DLT_>		INTAL		
>_DLT_>	*	[redacted]	[redacted]	[redacted]
>_ADD_>	@		20MG	N16990 001

SOLUTION/DROPS; OPHTHALMIC

CROLOM

AT		BAUSCH AND LOMB	4%	N74443 001
				JAN 30, 1995

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

CROLOM

*	[redacted]		4%	[redacted]
				JAN 30, 1995

CROMOLYN SODIUM

AT		ADV REMEDIES	4%	N74706 001
				APR 29, 1998

OPTICROM

AT	+	ALLERGAN	4%	N18155 001
				OCT 03, 1984
	@	[redacted]	4%	[redacted]
				[redacted]

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB		[redacted]	[redacted]	[redacted]
				NOV 30, 1994
AB		WATSON LABS	10MG	N74436 001
				NOV 30, 1994

CYCLOSPORINE

>_ADD_>		CAPSULE; ORAL		
>_ADD_>		NEORAL		
>_ADD_>	BX	NOVARTIS	25MG	N50715 001
>_ADD_>				JUL 14, 1995
>_ADD_>	BX		50MG	N50715 003
>_ADD_>				JUL 14, 1995
>_ADD_>	BX	+	100MG	N50715 002
>_ADD_>				JUL 14, 1995
		SANDIMMUNE		
>_ADD_>	BX	NOVARTIS	25MG	N50625 001
>_ADD_>				MAR 02, 1990
>_ADD_>	BX		50MG	N50625 003
>_ADD_>				NOV 23, 1992
>_ADD_>	BX	+	100MG	N50625 002
>_ADD_>				[redacted]
>_DLT_>			[redacted]	[redacted]
>_DLT_>				[redacted]
>_DLT_>			[redacted]	[redacted]
>_DLT_>				[redacted]
>_DLT_>		*	[redacted]	[redacted]
>_DLT_>				[redacted]

CYCLOSPORINE

> DLT >		CAPSULE, MICROEMULSION; ORAL			
> DLT >		NEORAL			
> DLT >		NOVARTIS	25MG		N50715 001
> DLT >					JUL 14, 1995
> DLT >			50MG		N50715 003
> DLT >					JUL 14, 1995
> DLT >		*	100MG		N50715 002
> DLT >					JUL 14, 1995
> ADD >		SOLUTION; ORAL			
> ADD >		NEORAL			
> ADD >	BX	+ NOVARTIS	100MG/ML		N50716 001
> ADD >					JUL 14, 1995
		SANDIMMUNE			
> ADD >	BX	+ NOVARTIS	100MG/ML		N50574 001
> ADD >					NOV 14, 1983
> DLT >		*	100MG/ML		N50574 001
> DLT >					NOV 14, 1983
> DLT >		SOLUTION, MICROEMULSION; ORAL			
> DLT >		NEORAL			
> DLT >		* NOVARTIS	100MG/ML		N50716 001
> DLT >					JUL 14, 1995

DACARBAZINE

		INJECTABLE; INJECTION			
> ADD >		DACARBAZINE			
> ADD >	AP	GENSIA SICOR PHARMS	200MG/VIAL		N75259 002
> ADD >					AUG 27, 1998
		DTIC-DOME			
> ADD >	AP	+ BAYER	200MG/VIAL		N17575 002

DACTINOMYCIN

		INJECTABLE; INJECTION			
		COSMEGEN			
		+ MERCK	0.5MG/VIAL		N50682 001
		* MERCK SHARP DOHME	0.5MG/VIAL		N50682 001

DALTEPARIN SODIUM

		INJECTABLE; INJECTION			
		FRAGMIN			
		* PHARMACIA AND UPJOHN	10,000 IU/3.5ML		N20287 004
					JAN 30, 1998
		+	10,000 IU/ML		N20287 004
					JAN 30, 1998

DANAZOL

		CAPSULE; ORAL			
		DANAZOL			
AB		BARR	50MG		N74582 003
					MAY 29, 1998
AB			100MG		N74582 002
					MAY 29, 1998
		DANOCRINE			
AB		SANOFI	50MG		N17557 003
AB			100MG		N17557 004

DAUNORUBICIN HYDROCHLORIDE

		INJECTABLE; INJECTION			
		CERUBIDINE			
		+ BEDFORD	EQ 20MG BASE/VIAL		N64103 001
					FEB 03, 1995
		DAUNORUBICIN HCL			
		* BEDFORD	EQ 20MG BASE/VIAL		N64103 001
					FEB 03, 1995
		DAUNORUBICIN HCL PRESERVATIVE FREE			
AP		+ BEDFORD	EQ 20MG BASE/VIAL		N50731 001
					JAN 30, 1998
AP		GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL		N64212 001
					JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

		TABLET; ORAL-28			
		MIRCETTE			
		+ ORGANON	0.15MG;0.02MG		N20713 001
					APR 22, 1998

DESOXIMETASONE

GEL; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.05%		N74904 001 JUL 14, 1998
	TOPICORT			
AB	+ HOECHST MARION RSSL	0.05%		N18586 001 MAR 29, 1982

OINTMENT; TOPICAL

	DESOXIMETASONE			
AB	ALTANA	0.25%		N73440 001 APR 01, 1998

DEXAMETHASONE SODIUM PHOSPHATE

[redacted]; METERED; INHALATION

	DECADRON			
	* [redacted]	[redacted]		[redacted]
	●	EQ 0.1MG PHOSPHATE/INH		N13413 001

[redacted]; NASAL

	DECADRON			
	* [redacted]	[redacted]		[redacted]
	●	EQ 0.1MG PHOSPHATE/INH		N14242 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	DEXEDRINE			
[redacted]	* [redacted]	[redacted]		[redacted]
AA		5MG		N84935 001
	DEXTROSTAT			
[redacted]	[redacted]	[redacted]		[redacted]
AA	+	5MG		N84051 001

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 10% IN PLASTIC CONTAINER			
AP	B BRAUN	10GM/100ML		N18046 001
[redacted]	[redacted]	[redacted]		[redacted]
	DEXTROSE 5% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML		N16730 001
AP		50MG/ML		N16730 002

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 5% IN PLASTIC CONTAINER			
[redacted]	[redacted]	[redacted]		[redacted]
[redacted]	[redacted]	[redacted]		[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

	ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML		N19873 001 JUN 10, 1993
	[redacted]	[redacted]		[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML		N19844 001 JUN 10, 1993
	[redacted]	[redacted]		[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

	ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML		N19843 001 AUG 09, 1993
[redacted]	[redacted]	[redacted]		[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	
AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N18744 001 NOV 09, 1982	
AP	MCGAW	5GM/100ML;75MG/100ML	N18744 001 NOV 09, 1982	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	10GM/100ML;900MG/100ML	N18047 001
	● MCGAW	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	5GM/100ML;900MG/100ML	N18026 001
	● MCGAW	5GM/100ML;900MG/100ML	N18026 001

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AB	MARSAM	5MG/ML	N72371 001 JAN 29, 1993
	●	5MG/ML	N72371 001 JAN 29, 1993

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM

>ADD>	AB	◆ CIBA	50MG	N20142 002 NOV 24, 1993

DICLOFENAC POTASSIUM

>ADD>	AB	TEVA	50MG	N75219 001 AUG 06, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

>ADD>	AB	ALCON	0.1% †	N20809 001 MAY 04, 1998

VOLTAREN

>ADD>	AB	◆ CIBA	0.1%	N20037 001 MAR 28, 1991

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

	AB	BARR	20MG	N84600 001 JUL 29, 1985
		●	20MG	N84600 001 JUL 29, 1985

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

>ADD>	AB	ALTANA	0.05%	N75187 001 MAR 30, 1998

† SEE SECTION 1.4 OF INTRODUCTION

DIFLORASONE DIACETATE

CREAM; TOPICAL
PSORCON

AB	+ DERMIK LABS	0.05%	N20205 001 NOV 20, 1992	
RX	*	0.05%	N20205 001 NOV 20, 1992	

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

>ADD>	AP ABBOTT	0.25MG/ML	N40206 001 AUG 28, 1998	
>ADD>				

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

	@ ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998	
	@	180MG	N74752 001 JUL 09, 1998	
	@	240MG	N74752 003 JUL 09, 1998	
	@	300MG	N74752 004 JUL 09, 1998	

DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002 MAR 18, 1998	
AB2		180MG	N75124 003 MAR 18, 1998	
AB2		240MG	N75124 001 MAR 18, 1998	

DILTIAZEM XR

>ADD>				
>ADD>	AB2 TORPHARM	240MG	N74943 001 AUG 06, 1998	
>ADD>				

TIAZAC

BC	BIOVAIL	120MG	N20401 001 SEP 11, 1995	
BC	+	120MG	N20401 001 SEP 11, 1995	
BC		180MG	N20401 002 SEP 11, 1995	
BC	+	180MG	N20401 002 SEP 11, 1995	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TIAZAC

BC	BIOVAIL	240MG	N20401 003 SEP 11, 1995	
BC	+	240MG	N20401 003 SEP 11, 1995	
BC		300MG	N20401 004 SEP 11, 1995	
BC	+	300MG	N20401 004 SEP 11, 1995	
		360MG	N20401 005 SEP 11, 1995	
	+	360MG	N20401 005 SEP 11, 1995	

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998	
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998	

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

>ADD>	+ HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996	
>ADD>				
>ADD>	+	EQ 180MG HCL	N20506 002 OCT 04, 1996	
>ADD>				
>ADD>	+	EQ 240MG HCL	N20506 003	
>ADD>				
>DLT>	* MERCK	EQ 120MG HCL	[illegible]	
>DLT>				
>DLT>	*	EQ 180MG HCL		
>DLT>				
>DLT>	*	EQ 240MG HCL		
>DLT>				

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

	* CONTROLLED THERAP	10MG	[illegible]	

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	FOREST LABS	10MG	N20411 001	MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA	PUREPAC PHARM	12.5MG/5ML	N83237 001	JAN 25, 1982
	●	12.5MG/5ML	N83237 001	JAN 25, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP	BEDFORD	5MG/ML	N74939 001	APR 13, 1998

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

	● KV PHARM	EQ 100MG BASE	N71329 001	AUG 13, 1998

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001	JUN 25, 1998
AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001	FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001	MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT

+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001	APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	ROXANE LABS	EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991
AB	WATSON LABS	EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

AP	BRISTOL MYERS	10MG/VIAL	N62926 001	APR 13, 1989
AP		50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001	APR 13, 1989
AP		50MG/VIAL	N62926 002	APR 13, 1989
		100MG/VIAL	N62926 003	APR 13, 1989

DROPERIDOL

INJECTABLE; INJECTION
INAPSINE

> ADD >	AP	+ AKORN MFG	2.5MG/ML	N16796 001	

DROPERIDOL

INJECTABLE; INJECTION
INAPSINE

>_DLT_>	AP	* [illegible]	[illegible]	[illegible]	[illegible]

DYPHYLLINE

INJECTABLE; INJECTION
DIHYDROXYPROPYL THEOPHYLLINE

	* TEVA	250MG/ML	N09088 001
	●	250MG/ML	N09088 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	ABBOTT	10MG/ML	N40131 001 FEB 24, 1998

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

	BRISTOL MYERS SQUIBB	25MG	N18981 002 DEC 24, 1986
		35MG	N18981 003 DEC 24, 1986
	●	25MG	N18981 002 DEC 24, 1986
	●	35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

	+ RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
	+	60MG/0.6ML	N20164 003 MAR 27, 1998
	+	80MG/0.8ML	N20164 004 MAR 27, 1998
	+	100MG/ML	N20164 005 MAR 27, 1998

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN

	+ COR	75MG/100ML	N20718 002 MAY 18, 1998
	+	2MG/ML	N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT	[illegible]	[illegible]	[illegible]
AT	AKORN	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

>_DLT_>	* [illegible]	[illegible]	[illegible]
>_DLT_>			
>_ADD_>	+ HEALTHPOINT	2%	N50584 001 JAN 10, 1985
>_ADD_>			

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

AB	* [illegible]	[illegible]	[illegible]
AB		333MG	N60272 002

ERY-TAB

AB	[illegible]	[illegible]	[illegible]
AB	+	250MG	N62298 001
AB		[illegible]	[illegible]
AB	+	333MG	N62298 003 MAR 29, 1982
AB		[illegible]	[illegible]
AB	+	500MG	N62298 002

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

	● EC-[illegible]	[illegible]	[illegible]
	●	[illegible]	[illegible]

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

+	BAXTER PHARM PROD	10MG/ML	N19386 001	
			AUG 15, 1988	
●		100MG/ML	N19386 003	> ADD >
			DEC 31, 1986	> ADD >
+		250MG/ML	N19386 002	> ADD >
			DEC 31, 1986	> ADD >
+	CORMEDA	10MG/ML	N19386 001	> ADD >
			AUG 15, 1988	> ADD >
●		100MG/ML	N19386 003	> ADD >
			DEC 31, 1986	> ADD >
+		250MG/ML	N19386 002	> ADD >
			DEC 31, 1986	> ADD >
				> ADD >

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB	ROXCE LABS	1MG	N74818 001	
			AUG 19, 1997	
AB		2MG	N74818 002	
			AUG 19, 1997	
AB	WATSON LABS	1MG	N74818 001	
			AUG 19, 1997	
AB		2MG	N74818 002	
			AUG 19, 1997	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA

BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001	
			DEC 20, 1996	
BX		0.075MG/24HR	N20655 002	
			DEC 20, 1996	
BX		0.1MG/24HR	N20655 003	
			DEC 20, 1996	
BX	THERATECH	0.05MG/24HR	N20655 001	
			DEC 20, 1996	
BX		0.075MG/24HR	N20655 002	
			DEC 20, 1996	
BX		0.1MG/24HR	N20655 003	
			DEC 20, 1996	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA

BX	+ BERLEX	0.075MG/24HR	N20375 003	
			MAR 23, 1998	

ESCLIM

BX	FOURNIER	0.025MG/24HR	N20847 001	
			AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002	
			AUG 04, 1998	
BX		0.05MG/24HR	N20847 003	
			AUG 04, 1998	
BX		0.075MG/24HR	N20847 004	
			AUG 04, 1998	
BX		0.1MG/24HR	N20847 005	
			AUG 04, 1998	

FEMPATCH

BX	+ PARKE DAVIS	0.025MG/24HR	N20417 001	
			DEC 03, 1996	

TABLET; ORAL
ESTRADIOL

AB	ENDEAVOR	0.5MG	N40138 001	
			JAN 30, 1998	
AB		1MG	N40138 002	
			JAN 30, 1998	
AB		2MG	N40138 003	
			JAN 30, 1998	

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	RHONE POULENC RORER	0.05MG/24HR;0.14MG/24HR	N20870 001	
			AUG 07, 1998	
+		0.05MG/24HR;0.25MG/24HR	N20870 002	
			AUG 07, 1998	

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

+	PHARMACIA AND UPJOHN	1MG/ML	N85470 001
+		3MG/ML	N85470 002
●		1MG/ML	N85470 001
●		3MG/ML	N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN

AO	+	BRISTOL MYERS SQUIBB	20MG/ML	N09402 004	>ADD<	
AO	+		40MG/ML	N09402 003	>ADD<	
	+		10MG/ML	N09402 002	>DLT<	
AO	*	SQUIBB	20MG/ML	N09402 004	>DLT<	
AO	*		40MG/ML	N09402 003		
	*		10MG/ML	N09402 002		

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELADUMONE

@	BRISTOL MYERS SQUIBB	4MG/ML;90MG/ML	N09545 001	
@	SQUIBB	4MG/ML;90MG/ML	N09545 001	

DELADUMONE OB

@	BRISTOL MYERS SQUIBB	8MG/ML;180MG/ML	N09545 002	
@	SQUIBB	8MG/ML;180MG/ML	N09545 002	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPRO 14/14

>ADD<	+	WYETH AYERST	0.625MG,0.625MG;5MG,5MG	N20527 003	
>ADD<				JAN 09, 1998	

ESTRONE

INJECTABLE; INJECTION
THEELIN

@	PARKE DAVIS	1MG/ML	N03977 001	
@		2MG/ML	N03977 002	
@		5MG/ML	N03977 003	
@	PARKEDALE	1MG/ML	N03977 001	
@		2MG/ML	N03977 002	
@		5MG/ML	N03977 003	

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
EDECRIN

>ADD<	+	MERCK	EQ 50MG BASE/VIAL	N16093 001	
>DLT<	*	MERCK SHARP DOHME	EQ 50MG BASE/VIAL	N16093 001	

ETHACRYNIC ACID

TABLET; ORAL
EDECRIN

		MERCK	25MG	N16092 001	>ADD<
	+		50MG	N16092 002	>ADD<
		MERCK SHARP DOHME	25MG	N16092 001	>DLT<
	*		50MG	N16092 002	>DLT<

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVLITE

	BERLEX LABS	0.02MG;0.1MG	N20860 001	
			JUL 13, 1998	

LEVORA 0.15/30-21

AB	SEARLE	0.03MG;0.15MG	N73592 001	
			DEC 13, 1993	
AB	WATSON LABS	0.03MG;0.15MG	N73592 001	
			DEC 13, 1993	

TABLET; ORAL-28
LEVLITE

	BERLEX LABS	0.02MG;0.1MG	N20860 002	
			JUL 13, 1998	

LEVORA 0.15/30-28

AB	SEARLE	0.03MG;0.15MG	N73594 001	
			DEC 13, 1993	
AB	WATSON LABS	0.03MG;0.15MG	N73594 001	
			DEC 13, 1993	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	SEARLE	0.035MG;1MG	N71480 001	
			APR 12, 1988	
AB	WATSON LABS	0.035MG;1MG	N71480 001	
			APR 12, 1988	

TABLET; ORAL-28
NORETHIN 1/35E-28

AB	SEARLE	0.035MG;1MG	N71481 001	
			APR 12, 1988	
AB	WATSON LABS	0.035MG;1MG	N71481 001	
			APR 12, 1988	

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB		AESGEN	300MG	N74929 001 JAN 30, 1998
AB		TARO	200MG	N75078 001 APR 30, 1998
AB			300MG	N75078 002 APR 30, 1998

TABLET; ORAL
ETODOLAC

AB		CHELSEA LABS	400MG	N75069 001 APR 16, 1998
AB		MYLAN	400MG	N75104 001 FEB 06, 1998
AB		ROXCH LABS	400MG	N74893 001 APR 16, 1997
AB		TARO	400MG	N75074 001 MAR 11, 1998
AB		WATSON LABS	400MG	N74892 001 APR 16, 1997

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

	+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP		MARSAM	20MG/ML	N74968 001 JAN 09, 1998

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

ETOPOPHOS PRESERVATIVE FREE

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996
	+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

		MERCK	20MG	N20752 001 MAY 28, 1998
	+		40MG	N20752 002 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

[redacted]

	*	[redacted]	[redacted]	[redacted]
			20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

		ABBOTT	100MG	N19304 001 DEC 31, 1993
		[redacted]	[redacted]	[redacted]

TRICOR (MICRONIZED)

	+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENTANYL CITRATE

INJECTABLE; INJECTION
[redacted]

AP		ABBOTT	[redacted]	[redacted]
AP	*	[redacted]	[redacted]	[redacted]

FENTANYL CITRATE PRESERVATIVE FREE

AP		ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP		MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998

[redacted]

AP	*	JANSSEN	[redacted]	[redacted]

SUBLIMAZE PRESERVATIVE FREE

AP	+	JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FLOSEQUINAN

TABLET; ORAL
MANOPLAX
KNOLL PHARM 50MG N19960 001 DEC 30, 1992
75MG N19960 002 DEC 30, 1992
* 100MG N19960 003 DEC 30, 1992
@ 50MG N19960 001 DEC 30, 1992
@ 75MG N19960 002 DEC 30, 1992
@ 100MG N19960 003 DEC 30, 1992

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
AB DRAXIS HLTH 0.05% N72494 001 JAN 19, 1989
AB TARO 0.05% N72494 001 JAN 19, 1989

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP PHARMACIA AND UPJOHN 50MG/ML N81225 001 AUG 28, 1991
AP + 50MG/ML N81225 001 AUG 28, 1991

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE
AO KING PHARMS 25MG/ML N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN-N
* LILLY 0.05%;EQ 3.5MG BASE/GM N50346 001
@ 0.05%;EQ 3.5MG BASE/GM N50346 001

OINTMENT; TOPICAL
CORDRAN-N
* LILLY 0.05%;EQ 3.5MG BASE/GM N50345 001
@ 0.05%;EQ 3.5MG BASE/GM N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
@ SOLVAY 25MG N20243 001 DEC 05, 1994
25MG N20243 001 DEC 05, 1994

> ADD > **FOMIVIRSEN SODIUM**

> ADD > INJECTABLE; INJECTION
> ADD > VITRAVENE PRESERVATIVE FREE
> ADD > + ISIS 6.6MG/ML N20961 001
> ADD > AUG 26, 1998

GEMFIBROZIL

CAPSULE; ORAL
LOPID
@ PARKE DAVIS 200MG N18422 001
@ 300MG N18422 002
@ LARKE DAVIS PHARMS 200MG N18422 001
@ 300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
AB TORPHARM 600MG N75034 001 JUL 20, 1998

LOPID
AB + PARKE DAVIS 600MG N18422 003 NOV 20, 1986
AB + PARKE DAVIS PHARMS 600MG N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008	AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005	AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007	AUG 28, 1987
AP	MCGAW	EQ 40MG BASE/100ML	N62814 008	AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	[illegible]	[illegible]	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	[illegible]	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	[illegible]	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	[illegible]	AUG 28, 1987
AP		EQ 2MG BASE/ML	[illegible]	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	[illegible]	AUG 28, 1987

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001	JUN 22, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	INVAMED	1.5MG	N75174 001	JUN 22, 1998
AB		3MG	N75174 002	JUN 22, 1998
AB	MYLAN	1.5MG	N74792 001	JUN 26, 1998
AB		3MG	N74792 002	JUN 26, 1998

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

AT	* GLAXO WELLCOME	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	[illegible]	[illegible]
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	M60582 001	

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL
● SMITHKLINE BEECHAM — EQ 2MG BASE — N20305 002 JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR
[redacted] — [redacted] — [redacted]
EQ 200MG BASE — N20695 001 NOV 06, 1997
EQ 400MG BASE — N20695 002 MAY 14, 1998
+ EQ 600MG BASE — N20695 003 MAY 14, 1998

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

> DLT > [redacted]
> DLT > [redacted]
> DLT > [redacted]
> ADD > ● 10MG;25MG — N13553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL
[redacted] — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]
AB WATSON LABS — EQ 1MG BASE — N74762 001 JUN 25, 1997
AB — EQ 2MG BASE — N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL
[redacted] — [redacted] — [redacted]

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL
[redacted] — [redacted] — [redacted]
[redacted]
● 0.5MG — N71071 001 NOV 03, 1986
● 1MG — N71072 001 NOV 03, 1986
● 2MG — N71073 001 NOV 03, 1986
● 5MG — N71074 001 NOV 03, 1986
● 10MG — N71075 001 AUG 04, 1987
● 20MG — N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE
AQ BEDFORD — EQ 50MG BASE/ML — N74811 001 JAN 30, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL
[redacted] — [redacted] — [redacted]
[redacted]
● EQ 5MG BASE/ML — N72516 001 FEB 25, 1993
● EQ 5MG BASE/ML — N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

●	AM PHARM PARTNERS	10 UNITS/ML	N17029 017 DEC 05, 1985
●		100 UNITS/ML	N17029 018 DEC 05, 1985
●	FUTISANA	[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN LOCK FLUSH

AP	AM PHARM PARTNERS	10 UNITS/ML	N17029 007 MAY 06, 1982
AP		100 UNITS/ML	N17029 006
●		100 UNITS/ML	N17651 010
AP	FUTISANA	[illegible]	[illegible]
AP		[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN LOCK FLUSH PRESERVATIVE FREE

●	AM PHARM PARTNERS	10 UNITS/ML	N17029 011 SEP 22, 1987
●		100 UNITS/ML	N17029 012 SEP 22, 1987
●	FUTISANA	[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

●	AM PHARM PARTNERS	10 UNITS/ML	N17029 008 SEP 22, 1987
●		100 UNITS/ML	N17029 009 SEP 22, 1987
●	FUTISANA	[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN SODIUM

AP	AM PHARM PARTNERS	[illegible]	N17029 001
AP		[illegible]	N17979 001
AP		[illegible]	N17651 006
AP		[illegible]	N17029 003
AP		[illegible]	N17979 002
AP		[illegible]	N17029 004
●		[illegible]	N17651 005
●		5,000 UNITS/ML	N17029 002
●		5,000 UNITS/ML	N17979 003

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

●	AM PHARM PARTNERS	[illegible]	N17651 003
●		[illegible]	N17651 008
[illegible]	FUTISANA	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]
[illegible]		[illegible]	[illegible]
[illegible]		[illegible]	[illegible]
[illegible]		[illegible]	[illegible]
[illegible]		[illegible]	[illegible]
●		[illegible]	[illegible]
●		[illegible]	[illegible]
●		[illegible]	[illegible]
●		[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
●		200 UNITS/100ML	N19042 001 MAR 29, 1985
AP	MCGAW	[illegible]	[illegible]
●		[illegible]	[illegible]

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	[illegible]	[illegible]
●		10,000 UNITS/100ML	N18911 006 JAN 30, 1985

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	[illegible]	[illegible]
●		5,000 UNITS/100ML	N18911 007 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	[illegible]	[illegible]
		5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

●	B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
●	MCGAW	[illegible]	[illegible]

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985
	@	MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
AP		MCGAW	4,000 UNITS/100ML	N19952 001 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

AP		ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985
AP			10,000 UNITS/100ML	N18911 008 JAN 30, 1985
	@		5,000 UNITS/100ML	N18911 009 JAN 30, 1985
	@		10,000 UNITS/100ML	N18911 008 JAN 30, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP			10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985
AP		MCGAW	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP			10,000 UNITS/100ML	N19952 005 JUL 20, 1992
	@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@	B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992
	@	MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
	@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992
	@	MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
	@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
	@	MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP			5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP			10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP			20,000 UNITS/ML	N17029 016 DEC 05, 1985
AP		FUJISAWA	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP			5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP			10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP			20,000 UNITS/ML	N17029 016 DEC 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	◆	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986
AP	◆	FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986

HEPFLUSH-10

AP		AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984
AP		FUJISAWA	10 UNITS/ML	N17651 009 JUN 26, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

> DLT >			APRESOLINE			
> DLT >	AP	+	NOVARTIS	20MG/ML	N08303 003	
> ADD >		@		20MG/ML	N08303 003	
			HYDRALAZINE HCL			
> DLT >	AP		SOLOPAX	20MG/ML	N88517 001 AUG 22, 1985	
> DLT >						
> ADD >	AP	+		20MG/ML	N88517 001 AUG 22, 1985	
> ADD >						

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

		AVAPRO HCT			
	@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997	
	+		12.5MG;150MG	N20758 002 SEP 30, 1997	
		IRBESARTAN-HYDROCHLOROTHIAZIDE			
	@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997	
	+		12.5MG;150MG	N20758 002 SEP 30, 1997	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

		METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB		INVAMED	15MG;250MG	N70829 001 MAR 09, 1987	
AB			25MG;250MG	N70830 001 MAR 09, 1987	
	@		15MG;250MG	N70829 001 MAR 09, 1987	
	@		25MG;250MG	N70830 001 MAR 09, 1987	

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

			HYDROPRES 25			
> ADD >	BP		MERCK	25MG;0.125MG	N11958 002	
> DLT >	BP		MERCK SHARP DOHME	25MG;0.125MG	N11958 002	
			HYDROPRES 50			
> ADD >	BP	+	MERCK	50MG;0.125MG	N11958 003	

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

			HYDROPRES 50			
> DLT	BP	+	MERCK SHARP DOHME	50MG;0.125MG	N11958 003	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

		SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE		
AB		GENEVA PHARMS	25MG;25MG	N86881 001
		SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE		
AB		GENEVA PHARMS	25MG;25MG	N86881 001

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

		TIMOLIDE 10-25			
> ADD >	+	MERCK	25MG;10MG	N18061 001	
> DLT >	+	MERCK SHARP DOHME	25MG;10MG	N18061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	BARR	25MG;37.5MG	N74970 001 JAN 06, 1998	

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	BARR	25MG;37.5MG	N71251 002 MAY 05, 1998	

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

	DIOVAN HCT			
	NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998	
+		12.5MG;160MG	N20818 002 MAR 06, 1998	

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

AT		PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984
AT		PARKEDALE	2.5%	N88250 001 JUN 06, 1984

SOLUTION; TOPICAL

TEXACORT

AT	+	GENDERM	1%	N80425 001
AT	+	MEDICIS	1%	N80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

> DLT >	AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001
> ADD >	AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC

CORTISPORIN

		@	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001
	AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

> ADD >	AB		COPLEY PHARM	0.2%	N74489 001 AUG 12, 1998
> ADD >	AB		TARO	0.2%	N75042 001 AUG 25, 1998

WESTCORT

> ADD >	AB	+	WESTWOOD SQUIBB	0.2%	N17950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

> ADD >	AB		TARO	0.2%	N75043 001 AUG 25, 1998

WESTCORT

> ADD >	AB	+	WESTWOOD SQUIBB	0.2%	N18726 001 AUG 08, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA	+	KNOLL PHARM	5MG/5ML	N19891 001 DEC 07, 1992

HYDROMORPHONE HCL

AA		ROXANE	5MG/5ML	N74653 001 JUL 29, 1998

TABLET; ORAL

DILAUDID

AB	+	KNOLL PHARM	8MG	N19892 001 DEC 07, 1992

HYDROMORPHONE HCL

AB		ROXANE	8MG	N74597 001 JUL 29, 1998

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

	+	AKORN	1%;0.25%	N19261 001 JAN 30, 1992
	+	ALLERGAN	1%;0.25%	N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		MYLAN	200MG	N40274 001 MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

AB		ROYCE LABS	200MG	N40133 001 NOV 30, 1995
AB		WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

DROXIA

		BRISTOL MYERS SQUIBB	300MG	N16295 003 FEB 28, 1998

HYDROXYUREA

CAPSULE; ORAL

	DROXIA			
	BRISTOL MYERS SQUIBB	200MG	N16295 002	
			FEB 25, 1998	
		300MG	N16295 003	
			FEB 25, 1998	
	+	400MG	N16295 004	
			FEB 25, 1998	
	HYDREA			
AB	+ BRISTOL MYERS SQUIBB	500MG	N16295 001	
AB	+ SQUIBB	500MG	N16295 001	
	HYDROXYUREA			
AB	DURAMED	500MG	N75020 001	
			JUL 30, 1998	

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
AB	ROYCE LABS	10MG	N81149 001	
			MAR 18, 1994	
AB		25MG	N81150 001	
			MAR 18, 1994	
AB		50MG	N81151 001	
			MAR 18, 1994	
AB	WATSON LABS	10MG	N81149 001	
			MAR 18, 1994	
AB		25MG	N81150 001	
			MAR 18, 1994	
AB		50MG	N81151 001	
			MAR 18, 1994	

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL			
BX	AM HOME PRODS	100MG/5ML	N19833 002	
			SEP 19, 1989	
BX	WHITEHALL ROBINS	100MG/5ML	N19833 002	
			SEP 19, 1989	
	IBUPROFEN			
AB	ALPHARMA	100MG/5ML	N74978 001	
			MAR 25, 1998	> ADD >
	MOTRIN			> ADD >
AB	+ MCNEIL	100MG/5ML	N19842 001	> ADD >
			SEP 19, 1989	

IBUPROFEN

SUSPENSION; ORAL

	MOTRIN			
BX	+ MCNEIL	100MG/5ML	N19842 001	
			SEP 19, 1989	

TABLET; ORAL

	IBUPROFEN			
AB	INVAMED	400MG	N72064 001	
			JAN 14, 1988	
AB		600MG	N72065 001	
			JAN 14, 1988	
AB		800MG	N71938 001	
			JAN 14, 1988	
	●	400MG	N72064 001	
			JAN 14, 1988	
	●	600MG	N72065 001	
			JAN 14, 1988	
	●	800MG	N71938 001	
			JAN 14, 1988	

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	1.25MG	N75105 001	
			JUL 23, 1998	
AB		2.5MG	N75105 002	
			JUL 23, 1998	
AB	TEVA	1.25MG	N74498 002	
			FEB 12, 1998	

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	EON	75MG	N74464 001	
			MAY 28, 1998	

INSULIN LISPRO

INJECTABLE; INJECTION

	HUMALOG PEN			
	+ LILLY	100 UNITS/ML	N20563 002	
			AUG 06, 1998	

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

AP	ELKINS SINN	51%	N74629 004 MAR 31, 1998

IOPAMIDOL-250

AP	ABBOTT	51%	N75005 001 FEB 24, 1998

IOPAMIDOL-300

AP	ABBOTT	61%	N75005 002 FEB 24, 1998

IOPAMIDOL-370

AP	ABBOTT	76%	N75005 003 FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

[redacted]	[redacted]	[redacted]
BERLEX LABS	40.6%	N19580 001 DEC 07, 1989

OSMOVIST 240

[redacted]	[redacted]	[redacted]
BERLEX LABS	51.3%	N19580 002 DEC 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	MALLINCKRODT	51%	N20923 001 MAY 28, 1998

OPTIRAY 320

+	MALLINCKRODT	68%	N20923 002 MAY 29, 1998

OPTIRAY 350

+	MALLINCKRODT	74%	N20923 003 MAY 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

[redacted]	[redacted]	[redacted]	[redacted]
+		0.018MG/1NH	N19085 001 DEC 29, 1986

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
●		2.5MG	N16191 002 APR 01, 1996
●		5MG	N16191 001 APR 01, 1996

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
+	US SURGCL		1%	N18310 001

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AP	+	PARKEDALE	[redacted]	N16812 002
AP	+		[redacted]	N16812 003
	+		[redacted]	N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

[redacted]	[redacted]	[redacted]	[redacted]

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

		ORUVAIL			
	*	[redacted]	[redacted]	[redacted]	[redacted]
			100MG	N19816 003	FEB 08, 1995
			150MG	N19816 002	FEB 08, 1995

LABETALOL HYDROCHLORIDE

TABLET; ORAL

		LABETALOL HCL			
> ADD >	AB	EON	100MG	N75113 001	AUG 04, 1998
> ADD >	AB		200MG	N75113 002	AUG 04, 1998
> ADD >	AB		300MG	N75113 003	AUG 04, 1998
> ADD >	AB	WATSON LABS	100MG	N75133 001	AUG 03, 1998
> ADD >	AB		200MG	N75133 002	AUG 03, 1998
> ADD >	AB		300MG	N75133 003	AUG 03, 1998
> ADD >	AB	ZENITH GOLDLINE	100MG	N74787 001	AUG 03, 1998
> ADD >	AB		200MG	N74787 002	AUG 03, 1998
> ADD >	AB		300MG	N74787 003	AUG 03, 1998

LACTULOSE

POWDER FOR RECONSTITUTION; ORAL

		LACTULOSE			
> DLT >		INALCO	10GM/PACKET	N74712 001	DEC 10, 1997
> ADD >	+		10GM/PACKET	N74712 001	DEC 10, 1997

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

> ADD >		LAMICTAL CD			
> ADD >		GLAXO WELLCOME	5MG	N20764 001	AUG 24, 1998
> ADD >			25MG	N20764 002	AUG 24, 1998
> ADD >	+		100MG	N20764 003	AUG 24, 1998

LEPIRUDIN

INJECTABLE; INJECTION

		REFLUDAN			
	+	HOECHST MARION RSSL	50MG/VIAL	N20807 001	MAR 06, 1998

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

> ADD >		LEUPROLIDE ACETATE			
> ADD >	AP	BEDFORD	1MG/0.2ML	N74728 001	AUG 04, 1998
> ADD >		LUPRON			
> ADD >	AP +	TAP HOLDINGS	1MG/0.2ML	N19010 001	APR 09, 1985

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

		LEVO-DROMORAN			
	+	ICN	2MG/ML	N08719 001	DEC 19, 1991
	*	[redacted]	[redacted]	[redacted]	[redacted]

TABLET; ORAL

		LEVO-DROMORAN			
	+	ICN	2MG	N08720 001	DEC 19, 1991
	*	[redacted]	[redacted]	[redacted]	[redacted]

LIDOCAINE

DISC; ORAL
XYLOCAINE

	ASTRA	10%	N14394 001
+	ASTRA PHARMS	10%	N14394 001

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA

+	ASTRA PHARMS	2.5%;2.5%	N20962 001 FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	AM PHARM PARTNERS	2%	N17584 001
AP		4%	N17584 002
AP	FUJISAWA	2%	N17584 001
AP		4%	N17584 002

LISINOPRIL

TABLET; ORAL
ZESTRIL

AB	+ ZENECA	2.5MG	N19777 005 APR 29, 1993
AB		2.5MG	N19777 005 APR 29, 1993
AB		10MG	N19777 002 MAY 19, 1988
AB	+	10MG	N19777 002 MAY 19, 1988

LORATADINE

TABLET; ORAL
CLARITIN REDITABS

	SCHERING	10MG	N20704 001 DEC 23, 1996

TABLET, ORALLY DISINTEGRATING; ORAL
CLARITIN REDITABS

+	SCHERING	10MG	N20704 001 DEC 23, 1996

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP	AKORN	2MG/ML	N74974 001 JUL 23, 1998
AP	TAYLOR	2MG/ML	N75025 001 JUL 23, 1998

TABLET; ORAL
LORAZEPAM

AB	ROXCE LABS	0.5MG	N72926 001 OCT 31, 1991
AB		1MG	N72927 001 OCT 31, 1991
AB		2MG	N72928 001 OCT 31, 1991
AB	WATSON LABS	0.5MG	N72926 001 OCT 31, 1991
AB		1MG	N72927 001 OCT 31, 1991
AB		2MG	N72928 001 OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	PHARMOS	0.2%	N20803 001 MAR 09, 1998

LOTEMAX

+	PHARMOS	0.5%	N20583 001 MAR 09, 1998
+		0.5%	N20841 001 MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

+	COCHRANE	EQ 25MG BASE/ML	N17658 001
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

+	COCHRANE	EQ 50MG BASE/ML	N18039 001
+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXITANE			
AB	COCENSYS	[redacted]		N17525 001
AB				N17525 002
AB	+			N17525 003
AB				N17525 004
AB	WATSON LABS			N17525 001
AB				N17525 002
AB	+			N17525 003
AB				N17525 004

TABLET; ORAL

LOXITANE			
@	COCENSYS	EQ 10MG BASE	N17525 006
@		EQ 25MG BASE	N17525 007
@		EQ 50MG BASE	N17525 008
@	WATSON LABS	EQ 10MG BASE	N17525 006
@		EQ 25MG BASE	N17525 007
@		EQ 50MG BASE	N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON			
+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001
+	DOW HICKAM	EQ 85MG BASE/GM	N16763 001

POWDER FOR RECONSTITUTION; TOPICAL

SULFAMYLON			
+	MYLAN	5%	N19832 003 JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER			
AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989
AP	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001 SEP 29, 1989

MALATHION

LOTION; TOPICAL

OVIDE			
@	GENDERM	0.5%	N18613 001 AUG 02, 1982
@	MEDICIS	0.5%	N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER			
AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993
AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993
MANNITOL 15% IN PLASTIC CONTAINER			
AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15% IN PLASTIC CONTAINER

AP	MCGAW	15GM/100ML	N20008 003 JUL 26, 1993

MANNITOL 20%

AP	B BRAUN	20GM/100ML	N14738 001
AP	MCGAW	20GM/100ML	N14738 001

MANNITOL 20% IN PLASTIC CONTAINER

AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993
AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993
AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N16772 002
	MCGAW	5GM/100ML	N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+	LAYTON	2.5MG	N10251 001
*	MERCK SHARP DOHME	2.5MG	N10251 001

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	A74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

AA	ROXCH LABS	50MG	N40186 001 JUN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

AA	WATSON LABS	50MG	N40186 001 JUN 30, 1997

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

*	HOECHST MARION RSSL	250MG	N20049 001 MAY 10, 1993
+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

AB	GENPLS	0.05MG;1MG	N71539 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N71539 001 APR 12, 1988

TABLET; ORAL-28

NORETHIN 1/50M-28

AB	GENPLS	0.05MG;1MG	N71540 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N71540 001 APR 12, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HCL

AA	ROXANE	10MG/ML	N40180 001 APR 30, 1998

TABLET; ORAL

METHADONE HCL

AA	EON	5MG	N40241 001 MAY 29, 1998
AA		10MG	N40241 002 MAY 29, 1998

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ECN	40MG	N75082 001	MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL

AP	NARSAM	100MG/ML	N89849 001	DEC 27, 1991
@		100MG/ML	N89849 001	DEC 27, 1991

TABLET; ORAL
FORBAXIN

> DLT > > DLT > > ADD > AA	FOREST LABS	750MG	N85136 001	
@		750MG	N85136 001	

METHOCARBAMOL

> DLT > > ADD > AA	INWOOD LABS	500MG	N85137 001	
@		500MG	N85137 001	

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	INVAGED	EQ 5MG BASE	N72436 001	JUN 22, 1989
AB		EQ 10MG BASE	N70850 001	FEB 03, 1987
@		EQ 5MG BASE	N72436 001	JUN 22, 1989
@		EQ 10MG BASE	N70850 001	FEB 03, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	ABBOTT	1MG/ML	N75160 001	JUL 06, 1998

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	150MG	N74865 001	APR 13, 1998
AB		200MG	N74865 002	APR 13, 1998
AB		250MG	N74865 003	APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	5MG/VIAL	N64144 001	APR 30, 1998
AP		20MG/VIAL	N64144 002	APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR

+	MERCK	EQ 10MG BASE	N20829 002	FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

+	MERCK	EQ 5MG BASE	N20830 001	FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

+	FAULDING	20MG	N20616 001	JUL 03, 1996
+		50MG	N20616 002	JUL 03, 1996
+		100MG	N20616 003	JUL 03, 1996
+	FAULDING SVCS	20MG	N20616 001	JUL 03, 1996
+		50MG	N20616 002	JUL 03, 1996

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

	+	FAULDING SVCS	100MG	N20616 003 JUL 03, 1996

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB		AB GENERICS	15MG	N74862 001 JUL 07, 1998
AB			30MG	N74862 002 JUL 07, 1998
AB			60MG	N74862 003 JUL 07, 1998
AB			100MG	N74769 001 JUL 02, 1998
AB			200MG	N74769 002 JUL 02, 1998

MS CONTIN

AB	+	PURDUE FREDERICK	15MG	N19516 003 SEP 12, 1989
AB	+		30MG	N19516 001 MAY 29, 1987
AB	+		60MG	N19516 002 APR 08, 1988
AB	+		100MG	N19516 004 JAN 16, 1990
AB	+		200MG	N19516 005 NOV 08, 1993
BC	+		15MG	N19516 003 SEP 12, 1989
BC	+		30MG	N19516 001 MAY 29, 1987
BC	+		60MG	N19516 002 APR 08, 1988
BC	+		100MG	N19516 004 JAN 16, 1990

> ADD > MYCOPHENOLATE MOFETIL HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > CELLCEPT

> ADD >	+	ROCHE GLOBAL	500MG/VIAL	N50758 001 AUG 12, 1998

NADOLOL

TABLET; ORAL
CORGARD

AB		BRISTOL MYERS SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004
AB		SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP		KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998
AP			20MG/ML	N74471 002 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP		ABBOTT	0.4MG/ML	N70172 001 SEP 24, 1986
	@		0.4MG/ML	N70172 001 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB		ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997
AB		WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB		BARR	50MG	N74918 001 MAY 08, 1998

REVIA

AB	+	DUPONT MERCK	50MG	N18932 001 NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+	SYNTEX	375MG	N20067 002 OCT 14, 1994
AB	+		500MG	N20067 003 OCT 14, 1994

NAPROXEN

AB		INVAMED	375MG	N75061 001 FEB 18, 1998
AB			500MG	N75061 002 FEB 18, 1998
AB		PUREPAC PHARM	375MG	N74936 001 FEB 24, 1998
AB			500MG	N74936 002 FEB 24, 1998
AB		TEVA	375MG	N75227 001 JUN 30, 1998
AB			500MG	N75227 002 JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB		AL HIKMA	EQ 250MG BASE	N74480 002 FEB 18, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

		GLAXO WELLCOME	EQ 1MG BASE	N20763 002 FEB 10, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

	+	GLAXO WELLCOME	EQ 2.5MG BASE	N20763 001 FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

		TEVA	EQ 350MG BASE	N60304 001
	+		EQ 350MG BASE	N60304 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

AT		GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001
AT		MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HCL

AB		GENPHARM	20MG	N74928 001 MAR 19, 1998
AB			30MG	N74928 002 MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

AB		3M	0.1MG/HR	N89771 001 AUG 30, 1996
AB1			0.1MG/HR	N89771 001 AUG 30, 1996
AB			0.2MG/HR	N89772 001 AUG 30, 1996
AB1			0.2MG/HR	N89772 001 AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		MINITRAN				
AB		3M	0.4MG/HR	N19773 001 AUG 30, 1996		
AB1			0.4MG/HR	N89773 001 AUG 30, 1996		
AB			0.6MG/HR	N89774 001 AUG 30, 1996		
AB1			0.6MG/HR	N89774 001 AUG 30, 1996		
		NITRO-DUR				
AB	+	KEY PHARMS	0.1MG/HR	N20145 001 APR 04, 1995		
AB1	+		0.1MG/HR	N20145 001 APR 04, 1995		
AB	+		0.2MG/HR	N20145 002 APR 04, 1995		
AB1	+		0.2MG/HR	N20145 002 APR 04, 1995		
AB	+		0.4MG/HR	N20145 004 APR 04, 1995		
AB1	+		0.4MG/HR	N20145 004 APR 04, 1995		
AB	+		0.6MG/HR	N20145 005 APR 04, 1995		
AB1	+		0.6MG/HR	N20145 005 APR 04, 1995		
		NITROGLYCERIN				
AB2		MYLAN	0.1MG/HR	N75033 001 FEB 06, 1998		
AB			0.2MG/HR	N74609 001 AUG 30, 1996		
AB2			0.2MG/HR	N74609 001 AUG 30, 1996		
AB			0.4MG/HR	N74607 001 AUG 30, 1996		
AB2			0.4MG/HR	N74607 001 AUG 30, 1996	> DLT >	
AB			0.6MG/HR	N74559 001 AUG 30, 1996	> ADD >	
AB?			0.6MG/HR	N74559 001 AUG 30, 1996		
		TRANSDERM-NITRO				
AB2	+	NOVARTIS	0.1MG/HR	N20144 001 FEB 27, 1996		
AB	+		0.2MG/HR	N20144 002 FEB 27, 1996		

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		TRANSDERM-NITRO			
AB2	+	NOVARTIS	0.2MG/HR	N20144 002 FEB 27, 1996	
AB	+		0.4MG/HR	N20144 003 FEB 27, 1996	
AB2	+		0.4MG/HR	N20144 003 FEB 27, 1996	
AB	+		0.6MG/HR	N20144 004 FEB 27, 1996	
AB2	+		0.6MG/HR	N20144 004 FEB 27, 1996	
BX	+		0.1MG/HR	N20144 001 FEB 27, 1996	

NORETHINDRONE

TABLET; ORAL

		NOR-QD		
+		BARR	0.35MG	N17060 001
+		WATSON LABS	0.35MG	N17060 001

NYSTATIN

SUSPENSION; ORAL

		NYSTATIN		
AA		UDL	100,000 UNITS/ML	N64142 001 JUN 25, 1998

OLANZAPINE

TABLET; ORAL

		ZYPREXA		
	@	LILLY	2.5MG	N20592 001 SEP 30, 1996
	+		2.5MG	N20592 001 SEP 30, 1996
	@		15MG	N20592 005 SEP 09, 1997
	@		20MG	N20592 006 SEP 09, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK 40MG N19810 002 JAN 15, 1998 >ADD> >DLT>

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
NORFLEX
AB + 3M 100MG N12157 001
ORPHENADRINE CITRATE
AB INVAMED 100MG N40284 001 JUN 19, 1998

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + ALZA 5MG/5ML N18211 001
AA + HOECHST MARION RSSL 5MG/5ML N18211 001

TABLET; ORAL
DITROPAN
AB + ALZA 5MG N17577 001
AB + HOECHST MARION RSSL 5MG N17577 001

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN
AP + KING PHARMS 10 USP UNITS/ML N18261 001
AP + PARKEDALE 10 USP UNITS/ML N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT 0.005MG/ML N20819 001 APR 17, 1998 >ADD> >DLT>

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA KING PHARMS EQ 250MG BASE N62310 001
AB + PARKE DAVIS EQ 250MG BASE N60321 001
AA + PARKEDALE EQ 250MG BASE N60521 001
AB EQ 250MG BASE N62310 001
PAROMOMYCIN SULFATE
AA CARACO EQ 250MG BASE N64171 001 JUN 30, 1997
AB EQ 250MG BASE N64171 001 JUN 30, 1997

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON
+ ALZA 100MG N20193 001 SEP 26, 1996
+ BAKER NORTON 100MG N20193 001 SEP 26, 1996

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
AB BIOVAIL 400MG N75028 001 JUL 20, 1998

PERMETHRIN

CREAM; TOPICAL
ELIMITE
AB + ALLERGAN 5% N19855 001 AUG 25, 1989
PERMETHRIN
AB ALPHARMA 5% N74806 001 JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
+ ROCHE 50MG;500MG N19358 001 AUG 11, 1990

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN
@ ROCHE 50MG;500MG N19358 001 AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
AA EON 37.5MG N88414 001 OCT 19, 1983
@ 37.5MG N88414 001 OCT 19, 1983

TABLET; ORAL
PHENTERMINE HCL
+ EON 30MG N88605 001 SEP 28, 1987
@ 30MG N88605 001 SEP 28, 1987

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE
AP BEDFORD 5MG/VIAL N40235 001 MAR 11, 1998

REGITINE
AP + NOVARTIS 5MG/VIAL N08278 003

PINDOLOL

TABLET; ORAL
PINDOLOL
AB PUREPAC PHARM 5MG N74125 001 APR 28, 1993
AB 10MG N74125 002 APR 28, 1993
@ 5MG N74125 001 APR 28, 1993
@ 10MG N74125 002 APR 28, 1993
AB ROYCE LABS 5MG N74437 001 FEB 27, 1995

PINDOLOL

TABLET; ORAL
PINDOLOL
AB ROYCE LABS 10MG N74437 002 FEB 27, 1995
AB WATSON LABS 5MG N74437 001 FEB 27, 1995
AB 10MG N74437 002 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER
+ LEDERLE EQ 40MG BASE/ML; EQ 5MG BASE/ML N50750 001 FEB 24, 1998
+ EQ 4GM BASE/100ML; EQ 500MG BASE/100ML N50750 003 FEB 24, 1998
+ EQ 60MG BASE/ML; EQ 7.5MG BASE/ML N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM
AB ROYCE LABS 10MG N74460 001 SEP 29, 1995
AB 20MG N74460 002 SEP 29, 1995
AB WATSON LABS 10MG N74460 001 SEP 29, 1995
AB 20MG N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
PEG-LYTE
AA INVAMED 236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT N73036 001 AUG 31, 1993

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	PEG-LYTE			
	@ INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001	AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

	AEROSPORIN			
AP	+ GLAXO WELLCOME	EQ 500,000 U BASE/VIAL	N62036 001	
	@	EQ 500,000 U BASE/VIAL	N62036 001	
	POLYMYXIN B SULFATE			
AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	N60716 001	
AP	PFIZER	EQ 500,000 U BASE/VIAL	N60716 001	

POWDER; FOR RX COMPOUNDING

	POLY-RX			
AA	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001	
	+	100,000,000 UNITS/BOT	N61578 001	
	POLYMYXIN B SULFATE			
AA	PADDOCK	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983
	@	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	APR 13, 1998

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE			
AP	B BRAUN	2MEQ/ML	N85870 001	
AP	MCGAW	2MEQ/ML	N85870 001	
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
> ADD > AP	+ ABBOTT	29.8MG/ML	N20161 006	
> ADD >				AUG 11, 1998
> ADD > AP	+ BAXTER HLTHCARE	29.8MG/ML	N19904 002	
> ADD >				DEC 26, 1989
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
> ADD > AP	+ ABBOTT	2.24GM/100ML	N20161 003	
> ADD >				AUG 11, 1998
> ADD > AP	+ BAXTER HLTHCARE	2.24GM/100ML	N19904 003	
> ADD >				DEC 26, 1989
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
> ADD > AP	+ ABBOTT	2.98GM/100ML	N20161 004	
> ADD >				AUG 11, 1998
> ADD > AP	+ BAXTER HLTHCARE	2.98GM/100ML	N19904 004	
> ADD >				DEC 26, 1989

TABLET, EXTENDED RELEASE; ORAL

> DLT >	TEN-K			
> DLT > BC	NOVARTIS	10MEQ	N19381 001	
> DLT >				APR 16, 1986
> ADD >	@	10MEQ	N19381 001	
> ADD >				APR 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

> DLT >	POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> DLT >	B BRAUN	37MG/100ML;900MG/100ML	N19708 001	
> DLT >				SEP 29, 1989
> ADD >	@	37MG/100ML;900MG/100ML	N19708 001	
> ADD >				SEP 29, 1989
> DLT >	POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> DLT >	B BRAUN	75MG/100ML;900MG/100ML	N19708 002	
> DLT >				SEP 29, 1989
> ADD >	@	75MG/100ML;900MG/100ML	N19708 002	
> ADD >				SEP 29, 1989
> DLT >	POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> DLT >	B BRAUN	110MG/100ML;900MG/100ML	N19708 003	
> DLT >				SEP 29, 1989
> ADD >	@	110MG/100ML;900MG/100ML	N19708 003	
> ADD >				SEP 29, 1989
> DLT >	POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> DLT >	B BRAUN	220MG/100ML;900MG/100ML	N19708 005	
> DLT >				SEP 29, 1989

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

> ADD > POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
> ADD > @ B BRAUN 220MG/100ML;900MG/100ML N19708 005 SEP 29, 1989
> DLT > POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
> DLT > AP B BRAUN 300MG/100ML;900MG/100ML N19708 006 SEP 29, 1989
> ADD > @ 300MG/100ML;900MG/100ML N19708 006 SEP 29, 1989

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
@ B BRAUN 75MG/100ML;900MG/100ML N18722 001 NOV 09, 1982
@ NCGAN 75MG/100ML;900MG/100ML N18722 001 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
@ B BRAUN 150MG/100ML;900MG/100ML N18722 002 NOV 09, 1982
@ NCGAN 150MG/100ML;900MG/100ML N18722 002 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
@ B BRAUN 220MG/100ML;900MG/100ML N18722 003 NOV 09, 1982
@ NCGAN 220MG/100ML;900MG/100ML N18722 003 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
@ B BRAUN 300MG/100ML;900MG/100ML N18722 004 NOV 09, 1982
@ NCGAN 300MG/100ML;900MG/100ML N18722 004 NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
PHARMACIA AND UPJOHN 0.5MG N20667 006 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL
PRE-PRED
AA WE PHARMS 15MG/5ML N40192 001 MAY 28, 1998

PREDNISOLONE
AA WE PHARMS 15MG/5ML N40192 001 MAY 28, 1998

PRELONE
AA + MURO 15MG/5ML N89081 001 FEB 04, 1986

TABLET; ORAL
PREDNISOLONE
BX DANBURY PHARMA 5MG N80354 001
BX + 5MG N80354 001
BX + GENEVA PHARMS 5MG N80339 001
@ 5MG N80339 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
> DLT > SULSTER
> DLT > AT + AKORN EQ 0.23% PHOSPHATE;10% N74511 001 JUL 30, 1996
> DLT >
> ADD > @ EQ 0.23% PHOSPHATE;10% N74511 001 JUL 30, 1996
> ADD >

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE
+ ELAN PHARMA 250MG/5ML N10401 001
+ WYETH AYERST 250MG/5ML N10401 001

TABLET; ORAL
MYSOLINE
AB + ELAN PHARMA 250MG N09170 002
+ 50MG N09170 003
AB + WYETH AYERST 250MG N09170 002
+ 50MG N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB		INVAMED	500MG	N89284 001 JUN 23, 1986
	@		500MG	N89284 001 JUN 23, 1986
AB		SIDMAK LABS NJ	250MG	N88958 001 DEC 02, 1985
	@		250MG	N88958 001 DEC 02, 1985

PROCAN SR

AB		PARKE DAVIS	500MG	N86065 001
AB			750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985
AB	+	PARKEDALE	500MG	N86065 001
AB	+		750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		MARSAM	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
	@		EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB		TRIGEN	EQ 5MG BASE	N40268 001 FEB 27, 1998
AB			EQ 10MG BASE	N40268 002 FEB 27, 1998
AB		ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB			EQ 10MG BASE	N40162 002 JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP		NARSAM	25MG/ML	N89463 001 MAY 02, 1988
AP			50MG/ML	N89477 001 MAY 02, 1988
	@		25MG/ML	N89463 001 MAY 02, 1988
	@		50MG/ML	N89477 001 MAY 02, 1988

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA		PUREPAC PHARM	65MG	N83278 001
	@		65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB		INVAMED	10MG	N71658 001 JUL 05, 1988
AB			20MG	N71687 001 JUL 05, 1988
AB			40MG	N71688 001 JUL 05, 1988
AB			60MG	N72197 001 JUL 05, 1988
AB			80MG	N71689 001 JUL 05, 1988
AB			90MG	N72198 001 JUL 05, 1988
	@		10MG	N71658 001 JUL 05, 1988

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

	@	INVAMED	20MG	N71687 001 JUL 05, 1988
	@		40MG	N71688 001 JUL 05, 1988
	@		60MG	N72197 001 JUL 05, 1988
	@		80MG	N71689 001 JUL 05, 1988
	@		90MG	N72198 001 JUL 05, 1988

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB		PUREPAC PHARM	200MG	N84003 001
	@		200MG	N84003 001

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB	+	ROBINS AH	300MG	N12796 002
AB	+	WYETH AYERST	300MG	N12796 002

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

		GLAXO WELLCOME	EQ 15MG BASE/ML	N19675 001 DEC 30, 1988
	+		EQ 15MG BASE/ML	N19675 001 DEC 30, 1988

TABLET; ORAL
RANITIDINE HCL

AB		MYLAN	EQ 150MG BASE	N74552 001 JUL 30, 1998
AB			EQ 300MG BASE	N74552 002 JUL 30, 1998
AB		RANBAXY	EQ 150MG BASE	N75000 001 JAN 30, 1998
AB			EQ 300MG BASE	N75000 002 JAN 30, 1998

RIFAMPIN

CAPSULE; ORAL
RIFADIN

AB		HOECHST MARION RSSL	150MG	N62303 001

RIFAMPIN

AB		EON	150MG	N64150 002 JAN 02, 1998

RIFAPENTINE

TABLET; ORAL
PRIFTIN

	+	HOECHST MARION RSSL	150MG	N21024 001 JUN 22, 1998

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

	+	PROCTER AND GAMBLE	30MG	N20835 001 MAR 27, 1998

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT

		MERCK	EQ 5MG BASE	N20864 001 JUN 29, 1998
	+		EQ 10MG BASE	N20864 002 JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT

		MERCK	EQ 5MG BASE	N20864 001 JUN 29, 1998
	+		EQ 10MG BASE	N20864 002 JUN 29, 1998

MAXALT-MLT

		MERCK	EQ 5MG BASE	N20865 001 JUN 29, 1998
	+		EQ 10MG BASE	N20865 002 JUN 29, 1998

SACROSIDASE

SOLUTION; ORAL
SUCRAID

+	ORPHAN MEDCL	8,500 IU/ML	N20772 001 APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

+	ROCHE	EQ 200MG BASE	N20828 001 NOV 07, 1997
+		200MG	N20828 001 NOV 07, 1997

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	ESI LEDERLE	5MG	N74641 001 AUG 02, 1996
AB	LEDERLE	5MG	N74641 001 AUG 02, 1996
AB	STASON	5MG	N74912 001 APR 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA

	PFIZER	25MG	N20895 001 MAR 27, 1998
		50MG	N20895 002 MAR 27, 1998
+		100MG	N20895 003 MAR 27, 1998

SIMVASTATIN

TABLET; ORAL
ZOCOR

	MERCK	5MG	N19766 001 DEC 23, 1991

SIMVASTATIN

TABLET; ORAL
ZOCOR

+	MERCK	40MG	N19766 004 DEC 23, 1991
+		5MG	N19766 001 DEC 23, 1991
		40MG	N19766 004 DEC 23, 1991
+		80MG	N19766 005 JUL 10, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	450MG/100ML	N19635 001 MAR 09, 1988
@		450MG/100ML	N18184 001
AP	MCGAW	450MG/100ML	N19635 001 MAR 09, 1988
@		450MG/100ML	N18184 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	900MG/100ML	N17464 001
AP		900MG/100ML	N19635 002 MAR 09, 1988
AP	MCGAW	900MG/100ML	N17464 001
AP		900MG/100ML	N19635 002 MAR 09, 1988

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

@	B BRAUN	3GM/100ML	N19635 003 MAR 09, 1988
@	MCGAW	3GM/100ML	N19635 003 MAR 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML	N19635 004 MAR 09, 1988
@	MCGAW	5GM/100ML	N19635 004 MAR 09, 1988

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

@	B BRAUN	1.87GM/100ML	N18186 001
@	MCGAW	1.87GM/100ML	N18186 001

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	B BRAUN	1.87GM/100ML	N20004 001	APR 21, 1992
AP	MCGAW	1.87GM/100ML	N20004 001	APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE

AA	SANOFI	453.6GM/BOT	N11287 001	
AA	+	453.6GM/BOT	N11287 001	

KIONEX

AA	PADDOCK	454GM/BOT	N40029 001	FEB 06, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN

>ADD>	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N20280 007	OCT 23, 1996

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

	@ BERLEX LABS	120MG	N19865 005	APR 20, 1994
		160MG	N19865 002	OCT 30, 1992
	*	240MG	N19865 003	OCT 30, 1992
		120MG	N19865 005	APR 20, 1994
	+	160MG	N19865 002	OCT 30, 1992
		240MG	N19865 003	OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%

AP	+	PHARMACIA AND UPJOHN	30%	N19942 001	DEC 30, 1993

LIPOSYN III 30%

AP	+	ABBOTT	30%	N20181 001	JAN 13, 1998

NUTRILIPID 10%

AP	+	B BRAUN	10%	N19531 001	MAY 28, 1993
AP	*	MCGAW	10%	N19531 001	MAY 28, 1993

NUTRILIPID 20%

AP	+	B BRAUN	20%	N19531 002	MAY 28, 1993
AP	*	MCGAW	20%	N19531 002	MAY 28, 1993

SPARFLOXACIN

TABLET; ORAL
ZAGAM

>ADD>	+	MYLAN	200MG	N20677 001	DEC 19, 1996
>ADD> >DLT> >DLT>	*	RHONE POULENC RORER	200MG	N20677 001	DEC 19, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	+	PFIZER	EQ 1GM BASE/VIAL	N60076 001	
			EQ 1GM BASE/2.5ML	N60111 001	
	+		EQ 1GM BASE/2.5ML	N60111 001	
AP		PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	*	APOTHECON	20MG/ML	N08847 001	
	@		20MG/ML	N08847 001	

SUCRALFATE

TABLET; ORAL
SUCRALFATE

AB	RATIOPHARM	1GM	N74415 001	JUN 08, 1998

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTA

AP	*	AKORN	EQ 0.05MG BASE/ML	N19050 001	MAY 04, 1984
AP	*	JANSSEN	EQ 0.05MG BASE/ML	N19050 001	MAY 04, 1984

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULF-10

AT	CIBA	10%	N80025 001	
	@	10%	N80025 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SEPTRA

>DLT>	AP	*	GLAXO WELLCOME	80MG/ML;16MG/ML	N18452 001
>ADD>	AP	*	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001

SUSPENSION; ORAL
COTRIM PEDIATRIC

AB	TEVA	200MG/5ML;40MG/5ML	N70028 001	JUN 02, 1987

SEPTRA

>DLT>	AB		GLAXO WELLCOME	200MG/5ML;40MG/5ML	N17598 001
>ADD>	AB		MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001

SMZ-TMP

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983

SMZ-TMP PEDIATRIC

AB	TEVA	200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983
AB		200MG/5ML;40MG/5ML	N70028 001	JUN 02, 1987

TABLET; ORAL
SEPTRA

>DLT>	AB		GLAXO WELLCOME	400MG;80MG	N17376 001
>ADD>	AB		MONARCH PHARMS	400MG;80MG	N17376 001

SEPTRA DS

>DLT>	AB		GLAXO WELLCOME	800MG;160MG	N17376 002
>ADD>	AB		MONARCH PHARMS	800MG;160MG	N17376 002

SMZ-TMP

AB	TEVA	400MG;80MG	N18242 001	
AB		800MG;160MG	N18242 002	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	400MG;80MG	N18242 001	
AB		800MG;160MG	N18242 002	

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

AB	SUPERPHARM	500MG	N89339 001	OCT 26, 1987
	@	500MG	N89339 001	OCT 26, 1987

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	PARKE DAVIS	EQ 10MG BASE	[redacted]	[redacted]
		EQ 20MG BASE		
		EQ 30MG BASE		
	*	EQ 40MG BASE		
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001	SEP 09, 1993

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX
PARKE DAVIS PHARMS — EQ 20MG BASE — N20070 002 SEP 09, 1993
EQ 30MG BASE — N20070 003 SEP 09, 1993
+ EQ 40MG BASE — N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF
+ FUJISAWA — EQ 1MG BASE — N50708 001 APR 08, 1994
+ EQ 5MG BASE — N50708 002 APR 08, 1994
+ FUJISAWA HLTHCARE — EQ 1MG BASE — N50708 001 APR 08, 1994
+ EQ 5MG BASE — N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF
+ FUJISAWA — EQ 5MG BASE/ML — N50709 001 APR 08, 1994
+ FUJISAWA HLTHCARE — EQ 5MG BASE/ML — N50709 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE — N/A — N17881 001 DEC 30, 1987
BS MERCK SHARP DOHME — N/A — N17881 001 DEC 30, 1987

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
DUPONT PHARMS — N/A — N18467 001 MAR 16, 1982

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
DUPONT — N/A — N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
GLUCOSCAN
AP DUPONT — N/A — N17907 001
@ N/A — N17907 001
TECHNESCAN GLUCEPTATE
AP DRAXIMAGE — N/A — N18272 001 JAN 27, 1982
N/A — N18272 001 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA
DRAXIMAGE — N/A — N18489 001 OCT 31, 1986
MERCK — N/A — N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT
AP DRAXIMAGE — N/A — N18035 001
AP MERCK SHARP DOHME — N/A — N18035 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA
AP DRAXIMAGE — N/A — N18511 001 DEC 29, 1989
AP MERCK — N/A — N18511 001 DEC 29, 1989

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

		AN-SULFUR COLLOID			
>ADD>	AP	CIS	N/A		N17858 001
>DLT>		@	N/A		N17858 001
		TECHLOID			
	AP	BRACCO	N/A		N16923 001
		@	N/A		N16923 001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	HYTRIN			
AB	ABBOTT	EQ 1MG BASE	N20347 001	DEC 14, 1994
AB	+	EQ 2MG BASE	N20347 002	DEC 14, 1994
AB		EQ 5MG BASE	N20347 003	DEC 14, 1994
AB		EQ 10MG BASE	N20347 004	DEC 14, 1994
	TERAZOSIN HCL			
AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001	MAR 30, 1998
AB		EQ 2MG BASE	N74823 002	MAR 30, 1998
AB		EQ 5MG BASE	N74823 003	MAR 30, 1998
AB		EQ 10MG BASE	N74823 004	MAR 30, 1998

TERBINAFINE

GEL; TOPICAL

	LAMISIL			
	+ NOVARTIS	1%	N20846 001	APR 29, 1998

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

	ANDRODERM			
RX	+ THERATECH	2.5MG/24HR	N20489 001	SEP 29, 1995

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

	ANDRODERM			
	+ THERATECH	2.5MG/24HR	N20489 001	SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	ACHROMYCIN V			
AB	ESI LEDERLE	250MG	N50273 003	
AB	+	500MG	N50273 001	
AB	LEDERLE	250MG	N50273 003	
AB	+	500MG	N50273 001	

TABLET; ORAL

	SUMYCIN			
	APOTHECON	50MG	N61147 003	
		100MG	N61147 002	
	@	50MG	N61147 003	
	@	100MG	N61147 002	

THALIDOMIDE

CAPSULE; ORAL

	THALOMID			
	+ CELGENE	50MG	N20785 001	JUL 16, 1998

THEOPHYLLINE

CAPSULE; ORAL

	ELIXOPHYLLIN			
RX	FOREST LABS	100MG	N85545 001	JUL 31, 1984
RX	+	200MG	N83921 001	JUL 31, 1984
	@	100MG	N85545 001	JUL 31, 1984
	@	200MG	N83921 001	JUL 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

	ELIXOPHYLLIN SR			
EC	FOREST LABS	125MG	N84826 001	JAN 23, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	BRONKODYL SR				
BC	FOREST LABS	250MG	N86826 002 JAN 29, 1985		
●		125MG	N86826 001 JAN 29, 1985		
●		250MG	N86826 002 JAN 29, 1985		

TABLET; ORAL

	QUIBRON-T				
+	MONARCH PHARMS	300MG	N88656 001 AUG 22, 1985		
*	ROBERTS LABS	300MG	N88656 001 AUG 22, 1985		

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR				
BC	KING PHARMS	300MG	N87563 001 JUN 21, 1983	> ADD >	AB
BC	MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983	> ADD >	AB
				> ADD >	AB
+				> DLT >	AB
				> DLT >	AB
*				> DLT >	AB

THIAMYLAL SODIUM

INJECTABLE; INJECTION

	SURITAL		
+	PARKE DAVIS	1GM/VIAL	N07600 003
+		5GM/VIAL	N07600 005
+		10GM/VIAL	N07600 009
●	PARKEDALE	1GM/VIAL	N07600 003
●		5GM/VIAL	N07600 005
●		10GM/VIAL	N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIORIDAZINE HCL		
AA	PHARM ASSOC	100MG/ML	N40213 001 MAY 29, 1998

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID		
●	ROCHE	125MG	N19979 001 MAR 24, 1993
+		250MG	N19979 002 OCT 31, 1991
●	SYNTEX	125MG	N19979 001 MAR 24, 1993
*		250MG	N19979 002 OCT 31, 1991

TIMOLOL MALEATE

TABLET; ORAL

	BLOCADREN			
	MERCK	5MG	N18017 001	AB
		10MG	N18017 002	AB
+		20MG	N18017 004	AB
	MERCK SHARP DOHME	5MG	N18017 001	AB
		10MG	N18017 002	AB
*		20MG	N18017 004	AB

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

	AGGRASTAT		
+	MERCK	EQ 0.05MG BASE/ML	N20913 001 MAY 14, 1998
+		EQ 0.25MG BASE/ML	N20912 001 MAY 14, 1998

TOLCAPONE

TABLET; ORAL

	TASMAR		
	ROCHE	100MG	N20697 001 JAN 29, 1998
+		200MG	N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL
PHARMACIA AND UPJOHN 1MG N20771 001 >ADD
MAR 25, 1998 >ADD >
\+ 2MG N20771 002 >DLT >
MAR 25, 1998 >DLT >

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX
\+ BOEHRINGER MANNHEIM 10MG/ML N20137 002
AUG 23, 1993
\+ ROCHE 10MG/ML N20137 002
AUG 23, 1993

TABLET; ORAL
DEMADEX
BOEHRINGER MANNHEIM 5MG N20136 001
AUG 23, 1993
10MG N20136 002
AUG 23, 1993
20MG N20136 003
AUG 23, 1993
\+ 100MG N20136 004
AUG 23, 1993
ROCHE 5MG N20136 001
AUG 23, 1993
10MG N20136 002
AUG 23, 1993
20MG N20136 003
AUG 23, 1993 >DLT >
\+ 100MG N20136 004 >DLT >
AUG 23, 1993 >ADD >

TRETINOIN

CREAM; TOPICAL
AVITA
AB \+ PENEDERM 0.025% N20404 003
JAN 14, 1997
AB 0.025% N20404 003
JAN 14, 1997

TRETINOIN

GEL; TOPICAL
AVITA
BT PENEDERM 0.025% N20400 001
JAN 29, 1998
BX 0.025% N20400 001
JAN 29, 1998
RETIN-A
\+ J AND J 0.025% N17579 002
BX \+ JOHNSON AND JOHNSON 0.025% N17579 002

SOLUTION; TOPICAL
RETIN-A
\+ J AND J 0.05% N16921 001
AT \+ JOHNSON AND JOHNSON 0.05% N16921 001
TRETINOIN
AT COPLEY PHARM 0.05% N74873 001
JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
@ ALPHARMA 0.025% N87797 001
JUN 07, 1982
AT [illegible] 0.025% N87797 001
JUN 07, 1982

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
[illegible]
SQUIBB EQ 4MG BASE/5ML N12515 001
@ EQ 4MG BASE/5ML N12515 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL
AB ZENITH GOLDLINE EQ 1MG BASE N87612 001
NOV 19, 1982
AB EQ 2MG BASE N87613 001
NOV 19, 1982
AB ZENITH LABS EQ 1MG BASE N87612 001
NOV 19, 1982

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	[illegible]	[illegible]	[illegible]	
				NOV 13, 1981

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC

>DLT>	AB	*	[illegible]	1%	[illegible]
>ADD>	AT	+	MONARCH PHARMS	1%	N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001	FEB 06, 1998
AA		5MG	N40184 002	FEB 06, 1998

TRIMEPRAZINE TARTRATE

>DLT>	CAPSULE, EXTENDED RELEASE; ORAL			
>DLT>	TEMARIL			
>DLT>	* ALLERGAN HERBERT	EQ 5MG BASE	[illegible]	
>ADD>	●	EQ 5MG BASE	N11316 004	
>DLT>	SYRUP; ORAL			
>DLT>	TEMARIL			
>DLT>	ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	[illegible]	
>ADD>	●	EQ 2.5MG BASE/5ML	N11316 003	
>DLT>	TABLET; ORAL			
>DLT>	TEMARIL			
>DLT>	* ALLERGAN HERBERT	EQ 2.5MG BASE	[illegible]	
>ADD>	●	EQ 2.5MG BASE	N11316 001	

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION
ARFONAD

*	ROCHE	50MG/ML	[illegible]

TRIMETHAPHAN CAMSYLATE

[illegible] INJECTION
ARFONAD

●	ROCHE	50MG/ML	N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN

>ADD>	AP	+	ROBERTS LABS	100MG/ML	N17530 001
>DLT>	AP	*	[illegible]	[illegible]	[illegible]

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

>DLT>	AB		[illegible]	[illegible]	[illegible]
>DLT>	AB	*		[illegible]	[illegible]
>DLT>					[illegible]
>ADD>	AB		MONARCH PHARMS	100MG	N17943 001
>ADD>	AB	+		200MG	N17943 003
>ADD>					JUL 14, 1982

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

+	US BIOSCIENCE	EQ 200MG BASE/VIAL	N20326 002 JUL 31, 1998

TROGLITAZONE

TABLET; ORAL
REZULIN

AB	[illegible]	[illegible]	[illegible]
AB		[illegible]	[illegible] JAN 29, 1997
AB		[illegible]	[illegible] AUG 04, 1997
AB		[illegible]	[illegible] JAN 29, 1997
AB	PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997

TROGLITAZONE

TABLET; ORAL
REZULIN

AB	PARKE DAVIS PHARMS	400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	AKORN	1%	[illegible]
	●	1%	N88447 001 AUG 28, 1985

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX

	+ SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
	+	150 IU/AMP	N19415 003 SEP 18, 1986

METRODIN

	+ SERONO	75 IU/AMP	[illegible]
	+	150 IU/AMP	[illegible]

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	MARSAM	2.5MG/ML	[illegible]
AP		2.5MG/ML	[illegible]
	●	2.5MG/ML	N72233 001 FEB 26, 1993
	●	2.5MG/ML	N73485 001 SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
VIRA-A

	● PARKE DAVIS	EQ 187.4MG BASE/ML	[illegible]
	● PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

OINTMENT; OPHTHALMIC
VIRA-A

	+ PARKE DAVIS	3%	[illegible]
	+ PARKEDALE	3%	N50486 001

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	B BRAUN	100%	N19633 001 FEB 29, 1988
AP	MCGAW	100%	[illegible]

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)
+ BRISTOL MYERS 250MG;250MG;65MG N20802 001 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON
+ HOECHST MARION RSEL 80MG;20MG N18685 001 DEC 09, 1983
80MG;20MG N18685 001 DEC 09, 1983
+ 160MG;40MG N18685 002 DEC 09, 1983

GAVISCON-2
+ HOECHST MARION RSEL 160MG;40MG N18685 002 DEC 09, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB
ECOLAB 4% N19258 002 JUL 22, 1986
HUNTINGTON LABS 4% N19258 002 JUL 22, 1986

CIDA-STAT
ECOLAB 2% N19258 001 JUL 22, 1986
HUNTINGTON LABS 2% N19258 001 JUL 22, 1986

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEK PHARM 100MG N75122 001 JUN 19, 1998
200MG N75122 002 JUN 19, 1998 >DLT>
NOVOPHARM 200MG N74961 001 JUN 19, 1998 >DLT>

CIMETIDINE

TABLET; ORAL
CIMETIDINE
PERRIGO 100MG N74972 001 JUN 19, 1998
PHARM FORM 200MG N74963 001 JUN 19, 1998
TORPHARM 100MG N74948 001 JUN 19, 1998

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX
COPLEY PHARM 100MG N73249 001 FEB 13, 1998

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED
+ WHITEHALL ROBINS 100MG/5ML N20589 002 NOV 07, 1997
100MG/5ML N20589 002 NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL
+ WHITEHALL ROBINS 100MG/2.5ML N20812 001 JAN 30, 1998

TABLET; ORAL
IBUPRIN
SIDMAK LABS NJ 200MG N71773 001 JUL 16, 1987
@ 200MG N71773 001 JUL 16, 1987

IBUPROFEN
NOVOPHARM 200MG N74931 001 JUL 20, 1998
PHARM FORM 200MG N74782 001 JUL 06, 1998

NUPRIN
BRISTOL MYERS 200MG N72034 001 FEB 16, 1988

IBUPROFEN

TABLET; ORAL
MOTRIN

> DLT >	BRISTOL MYERS	200MG	N72038 001	FEB 16, 1988
> DLT >	@	200MG	N72035 001	FEB 16, 1988
> ADD >	@	200MG	N72036 001	FEB 16, 1988
> ADD >	@ MCNEIL	200MG	N19012 001	MAY 18, 1984
> DLT >	@	200MG	N19012 003	JUL 29, 1987
> DLT >		200MG	N19012 001	MAY 18, 1984
> ADD >		200MG	N19012 003	JUL 29, 1987
> ADD >				

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN

	MCNEIL	100MG	N20601 003	NOV 15, 1996
	+	100MG	N20601 003	NOV 15, 1996

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R PEN

> ADD >	+ LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998
> ADD >				

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 70/30 PEN

> ADD >	+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002	AUG 06, 1998
> ADD >				

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3

	+ ADVANCED CARE PRODS	4%	N20827 001	MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

	NOVEX	2%	N74924 001	APR 29, 1998
	NU PHARM	2%	N74924 001	APR 29, 1998

MINOXIDIL (FOR WOMEN)

	NOVEX	2%	N74924 002	APR 29, 1998
	NU PHARM	2%	N74924 002	APR 29, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

	PAR PHARM	EQ 200MG BASE	N75168 001	JUL 28, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL

	MCNEIL	15MG/16HR	N20536 001	JUL 03, 1996
	+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001	JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75

	+ GLAXO WELLCOME	EQ 75MG BASE	N20745 001	FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUG '98

NO AUGUST 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Botulinum toxin type A TN= Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH, DD=08/12/1998
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
Infliximab TN= Remicade	Amended to: Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway Malvern, PA 19355 DD=11/14/1995 MA=08/24/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4, DD=01/06/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Lamotrigine TN= Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=08/23/1995 MA=08/24/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Octreotide TN= Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/12/1998
Octreotide TN= Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/13/1998
Octreotide TN= Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/13/1998
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Dept. of Neurology Philips Building, Suite 2Q; 10 Union Square New York, NY 10003 DD=04/30/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Tetrabenazine TN=	Treatment for moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998

Orphan Product Designations and Approvals List
January 1998 through August 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED	**PEDIATRIC EXCLUSIVITY**

REFERENCES

NEW DOSING *SCHEDULE*

D-38	**CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION**
D-39	**CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."**
D-40	**ONCE-A-DAY DOSING REGIMEN**
D-41	**DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS**
D-42	**TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE**
D-43	**INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD**
D-44	**IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED**
D-45	**ONCE DAILY DOSING FOR MAINTENANCE ONLY**
D-46	**NEW DOSING REGIMEN OF 80MG DAILY**

NEW INDICATION

I-212	**TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME**
I-213	**TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY**
I-214	**TREATMENT OF OSTEOPOROSIS**
I-215	**PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS**
I-216	**FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA .**
I-217	**PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY**
I-218	**USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482	004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
>ADD>	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015		I-235	SEP 23, 2001
	020560	001	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020560	002	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020511	001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	020304	001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
>ADD>	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
>ADD>	020441	002	BUDESONIDE;PULMICORT				D-45	OCT 08, 2001
	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
	020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
	020521	001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
	020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
>ADD>	020297	004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020822	002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
	020344	001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
	020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
				5653972	NOV 16, 2014	U-239		
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
				4462983	JUL 31, 2001	U-227		
				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
	020690	001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020690	002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
>ADD>	020972	001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
>ADD>	020972	002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
>ADD>	020972	003	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-217	JAN 30, 2001
							I-222	MAR 27, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
							I-217	JAN 30, 2001
>ADD>	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
>ADD>	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
>ADD>	020718	001	EPTIFIBATIDE;INTEGRILIN	5807825	SEP 15, 2015	U-244	NCE	MAY 18, 2003
				5756451	NOV 11, 2014			
				5686570	NOV 11, 2014			
>ADD>	020718	002	EPTIFIBATIDE;INTEGRILIN	5807825	SEP 15, 2015	U-244	NCE	MAY 18, 2003
				5756451	NOV 11, 2014			
				5686570	NOV 11, 2014			
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
>ADD>	020870	001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
>ADD>	020870	002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
>ADD>	020527	002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
>ADD>	020527	001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
							I-232	JUN 12, 2001
	020363	002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020363	003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139		
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020961	001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
>ADD>	020235	001	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
>ADD>	020235	002	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
>ADD>	020235	003	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
>ADD>	020882	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
>ADD>				4894476	MAY 02, 2008			
>ADD>				5084479	JAN 02, 2010			
>ADD>	020882	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
>ADD>				4894476	MAY 02, 2008			
>ADD>				5084479	JAN 02, 2010			
	019596	001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			
	020460	001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
				4642346	JUN 24, 2005			
				4507305	MAY 12, 2001	U-64		
	020509	001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020509	002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	019771	001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
				4552899*PED	MAY 12, 2003			
	019833	002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
				4788220*PED	MAY 29, 2006			
	020589	001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
				4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
	020516	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020601	001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020603	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020601	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020602	001	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
							PED	DEC 16, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019842	001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
				5374659*PED	JUN 20, 2012			
	020135	001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020135	002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020903	001	INTERFERON ALFA-2B;REBETRON	4530901	JUL 23, 2002		NP	JUN 03, 2001
				4211771	JUL 08, 1999	U-234		
				5767097	JAN 23, 2016	U-235		
	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
	020571	001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
>ADD>	020083	001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
>ADD>	020657	001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015			
>ADD>				4727064	FEB 23, 2005			
				4267179	JUN 23, 2000			
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
>ADD>	020310	001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
>ADD>				4335125	JUN 15, 1999			
>ADD>				5456851	APR 07, 2014			
	020241	001	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
	020241	002	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
	020241	003	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
	020241	004	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
	020241	005	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
	020241	006	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>							I-238	AUG 24, 2001
>ADD>	020764	001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
>ADD>				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
>ADD>	020764	002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
>ADD>				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
>ADD>	020764	003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
>ADD>				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
	020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001
	020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020905	001	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
>ADD>	020905	002	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
>ADD>	020905	003	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
	020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
							NCE	MAR 06, 2003
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
				4992554	FEB 12, 2008			
				5091169	FEB 25, 2009			
				5223243	JUN 29, 2010	U-237		
				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
>ADD>	018654	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
>ADD>				4280957*PED	JUN 20, 2000			
>ADD>	018654	002	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
>ADD>				4280957*PED	JUN 20, 2000			
>ADD>	020942	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
>ADD>				4280957*PED	JUN 20, 2000			
>ADD>	020415	003	MIRTAZAPINE;REMERON				NCE	JUN 14, 2001
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
	020829	002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
>ADD>	020933	001	NEVIRAPINE;VIRAMUNE				NDF	SEP 11, 2001
>ADD>							NCE	JUN 21, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010			
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
							I-230	JUN 30, 2001
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015			
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
>ADD>	020451	001	PORFIMER SODIUM;PHOTOFRIN	5145863	DEC 15, 2009	U-129		
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75				I-228	JUN 08, 2001
	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
	020864	001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
				5602162	MAY 10, 2015	U-240		
	020864	002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
				5602162	MAY 10, 2015	U-240		
	020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
				5602162	MAY 10, 2015	U-240		
	020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
				5602162	MAY 10, 2015	U-240		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020533	001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
>ADD>	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211	I-237	SEP 25, 2001
>ADD>				5380922	JAN 10, 2012		I-236	SEP 25, 2001
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
				D342994	JAN 04, 2008			
	020828	001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
	020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
>ADD>	020926	001	SEVELAMER HYDROCHLORIDE;RENAGEL				NCE	OCT 30, 2003
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
>ADD>	019766	001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
>ADD>							I-239	JUL 10, 2001
>ADD>	019766	002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
>ADD>							I-239	JUL 10, 2001
>ADD>	019766	003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
>ADD>							I-239	JUL 10, 2001
>ADD>	019766	004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
>ADD>							I-239	JUL 10, 2001
>ADD>	019766	005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005		NS	JUL 10, 2001
>ADD>							I-239	JUL 10, 2001
>ADD>							D-46	JUL 10, 2001
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
>ADD>	020887	001	TECHNETIUM TC-99M APCITIDE;ACUTECT				NCE	SEP 14, 2003
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
							ODE	JUL 16, 2005
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020671	001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
>ADD>	020281	001	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
>ADD>	020281	002	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020719	001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	003	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020720	001	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	002	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	003	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
>ADD>	020586	001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
>ADD>	020892	001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
>ADD>							ODE	SEP 25, 2005
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
>ADD>	020547	001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 27, 2010			
	020471	001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		

*U.S. Government Printing Office: 1998 — 454-723/00002

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
*** 8240**

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $78.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account _____ – ___
☐ VISA or MasterCard

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

( ) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature) (10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
2.8
2.5
3.2
2.2
3.6
2.0
1.8
6"